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Abstract
Background: Dietary intakes of the n-6 fatty acid linoleic acid (LA, 18:2n-6) have
increased dramatically during the 20th century. Replacing ﬁsh oil (FO) with veg-
etable oil (VO) in feed for farmed ﬁsh introduces LA and alters the fatty acid com-
position in Atlantic salmon (Salmo salar L.). LA is the precursor of arachidonic
acid (AA, 20:4n-6) the backbone of the endocannabinoids 2-arachidonoylglycerol
(2-AG) and anandamide (AEA). A sustained hyperactivity of the endocannabinoid
system is believed to play a causal role in the development of obesity and asso-
ciated metabolic disorders. Here we posit that excessive dietary intake of LA,
the precursor of AA, would induce endocannabinoid hyperactivity and promote
obesity.
Design: LA was isolated as an independent variable to reﬂect the dietary increase
in LA from 1 percent of energy (en%) to 8 en% occurring in the US during the 20th
century. Male C57BL/6j mice were exposed to 1 en% LA and 8 en% LA in diets of
35 en% and 60 en% fat from last week of gestation and 14 weeks from weaning
(Paper I), and in diets of 12.5 en% and 35 en% fat for 16 weeks from 6 weeks
of age (Paper II). To reduce tissue n-6 highly unsaturated fatty acids (HUFA), 1
en% eicosapentaenoic acid (EPA, 20:5n-3)/docosahexaenoic acid (DHA, 22:6n-3)
were supplemented to the 8 en% LA diets in Paper I. Atlantic salmon, 340 g, was
fed ﬁsh oil and soybean oil (SO) for 6 months. Male C57BL76j mice, 6 weeks of
age, were fed diets of 35 en% fat based on FO salmon ﬁllet (1 en% LA) and SO
salmon ﬁllet (8 en% LA) for 16 weeks (Paper III).
Results: Increasing dietary LA from 1 en% to 8 en% elevated AA in phospho-
lipids (AA -PL) with a subsequent elevation in liver 2-AG and anandamide as-
sociated with higher food intake, feed efﬁciency, weight gain and adiposity and
increased hypertrophy and inﬂammation of adipose tissue. Selectively reducing
LA to 1 en% reversed the obesogenic properties of a high fat diet. Reducing AA
-PL by EPA/DHA supplementation resulted in metabolic patterns resembling 1
en% LA diets. Replacing ﬁsh oil with soybean oil in feed for Atlantic salmon
elevated tissue LA and AA, and increased endocannabinoid activity and lipid ac-
cumulation in salmon liver. Mice fed SO salmon gained more weight, had larger
6
adipocytes and more adipose tissue inﬂammation than mice fed FO salmon.
Conclusion: Dietary LA of 8 en% LA induces hyperactivity of the endocannabi-
noid system and increase the risk of developing obesity and associated metabolic
disorders in mice. In a balanced diet, the adipogenic effect of LA can be prevented
by consuming sufﬁcient EPA and DHA to reduce the AA -PL pool and normal-
ize endocannabinoid tone. A dietary approach addressing an underlying cause of
endocannabinoid hyperactivity may prove to be a safe and viable alternative for
preventing and decreasing obesity.
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Chapter 1
Preface
In the 1960s, Americans consumed 45 en% of their energy from fats, 13% of
the population was obese (Flegal et al., 1998) and 1 % had diabetes type 2 (NDIC,
1995). In 2008, 72% of men and 64% of women were overweight or obese (Flegal
et al., 2002), 8% had diabetes, most of which were type 2 (CDC, 2011) and energy
intake from fat was reduced to 32 en% presumably due to dietary recommenda-
tions to reduce dietary fat to 20-35 en% (USDA, 2010). In the 1970s, Norwegians
consumed 40 en% fat and 14% were overweight (HOD, 2010). In 2008, 32%
of Norwegian men and 21% of women were overweight and dietary fat intakes
were reduced to 35 en% (HOD, 2010). Although low in a global perspective, the
percent of obese Norwegian adults has nearly doubled since 2000 (Figure 1.1).
Figure 1.1: The percent of obese adults worldwide. The prevalence of obesity in Norway is low
compare to countries like the United States and Mexico. Important to note, the increase in obese
adults in Norway from 2000 to 2009 is considerably higher than most other countries. c©OECD.
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Figure 1.2: Intake of soybean oil in the US. Estimated consumption of soybean oil (in red), the
major dietary source of n-6, in the US during the 20th century. Adapted with permission to reprint
from authors (Blasbalg et al., 2011).
The cause of obesity is multifactorial. Physical inactivity and poor diet, and
especially dietary fat have been associated with the development of obesity (Bray
and Popkin, 1998). As there is no link between a low fat diet and reduced weight
and disease (Beresford et al., 2006; Howard et al., 2006a,b), the type of dietary
fat speciﬁcally the imbalance in n-6 to n-3 polyunsaturated fatty acids (PUFA),
is emerging as a risk factor for developing obesity (Massiera et al., 2003; Ail-
haud et al., 2008; Madsen et al., 2008; Matias et al., 2008a,b). Dietary advices
to replace saturated fat (SFA) with PUFA and increasing use of vegetable oils in
cooking have lead to a dramatic increase in human consumption of soybean oil,
one of the major dietary sources of LA (Figure 1.2). In the US, the availability of
soybean oil increased from 2.2 en% to 7.3 en% during the 20th century whereas
the availability of α-linoleic acid (ALA, 18:3n-3), EPA and DHA decreased in the
same period (Blasbalg et al., 2011) causing a disequilibrium in the intakes of n-6
to n-3 PUFA. Norwegian dietary guidelines recommend increasing use of veg-
etable oils for cooking (Nasjonalt Råd for Ernæring, 2011) and the consumption
of vegetable oils in Norway has doubled since 1980 (HOD, 2010).
The endocannabinoid system is involved in the control of appetite and energy
balance, and is important in maintaining energy homeostasis. Overactivity of the
endocannabinoid system is believed to be one of the underlying causes of obesity,
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hyperglycemia, dyslipidemia, insulin resistance and type 2 diabetes (Di Marzo,
2008; Kunos et al., 2008), but has not as of yet been linked to the worldwide epi-
demic of obesity. Suppressing a hyperactive endocannabinoid tone is believed to
be a critical target for reducing obesity (Osei-Hyiaman et al., 2005). Pharmaceu-
tical drugs interrupting endocannabinoid signaling serve as potential candidates
for therapy and treatment of obesity and associated metabolic disorders (Després
et al., 2005; Van Gaal et al., 2005; Christopoulou and Kiortsis, 2011). However
serious psychiatric side-effects caused marketplace withdrawal of rimonabant, a
selective cannabinoid receptor antagonist (Christensen et al., 2007). No pharma-
ceutical alternatives are currently available, which urges the need for a dietary
alternative to reduce endocannabinoid hyperactivity. A dietary approach to pre-
vent endocannabinoid hyperactivity is likely to have widespread beneﬁcial public
health implications related to obesity and metabolic syndrome.
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Chapter 2
Introduction
Unless care is exercised in selecting food, a diet may result which is
one-sided or badly balanced - that is, one in which either protein or fuel
ingredients (carbohydrate and fat) are provided in excess [....] The evils
of overeating may not be felt at once, but sooner or later they are sure to
appear - perhaps in an excessive amount of fatty tissue, perhaps in general
debility, perhaps in actual disease. - Wilbur Olin Atwater, 1902
2.1 Dietary changes in n-6 and n-3 intakes
Humans evolved on a diet based on lean meat, ﬁsh, green leafy vegetables, fruits,
nuts and berries shaping the modern human’s genetic nutritional requirements
(Simopoulos, 1999). Major dietary changes in terms of dietary fat, especially
during last 150 years have changed the type and amount of fat for human con-
sumption. The evolutionary diet was based on a balanced intake of n-6 to n-3
fats. Cereal grains are one of the major contributors to the world’s food supply
and usually contain high levels n-6 and low levels of n-3 (Simopoulos, 1999). The
introduction of cereals into the human diet has contributed to a shift in the n-6 to
n-3 ratio. The use of grain feed in modern agriculture together with emphasis on
production have decreased the n-3 content in animal meat and animal products,
vegetables, eggs and ﬁsh (Simopoulos, 1999). In aquaculture, farmed Atlantic
salmon have traditionally been fed diets based on ﬁsh oil and ﬁsh meal (Turchini
et al., 2009). Today, marine resources are limited and the steady increase in aqua-
culture production volume of 8-10% per year (Tacon et al., 2006) has resulted
in increased use of alternative protein and oil sources in aqua feeds (Figure 2.1).
Vegetable oils are recognized as suitable alternatives to ﬁsh oils (Torstensen et al.,
2005; Turchini et al., 2009) but these oils are devoid of EPA and DHA and con-
tain high levels of LA and monounsaturated fat (MUFA). Replacing ﬁsh oil with
vegetable oil in feed for farmed ﬁsh reduce EPA and DHA and increase LA con-
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tent in ﬁsh ﬁllet (Grisdale-Helland et al., 2002; Torstensen et al., 2005; Turchini
et al., 2009). To ensure sustainability, ﬁsh farming implies a trade-off between
the amount of wild ﬁsh used in feed for Atlantic salmon and the amount of n-
3 PUFA in salmon ﬁllet (NIFES, 2011a). There have been increasing concerns
about the decreasing content of EPA and DHA in farmed Atlantic salmon. Nor-
wegian surveillance data (NIFES, 2011b) report a moderate increase in LA levels
in ﬁllets of farmed Atlantic salmon from 1.1 g / 100 g in 2005 to 1.6 g / 100 g in
2010 and a decrease in EPA + DHA from 2.7 g / 100 g to 2.1 g / 100 g in the same
period.
Figure 2.1: Composition of Norwegian-produced ﬁsh feed. The increase in aquaculture pro-
duction, presented as slaughtered ﬁsh (purple line), has lead to a replacement of ﬁsh meal (green
bar) and ﬁsh oil (red bar) with alternative plant protein and oil sources (blue bar) in Norwegian-
produced aqua feeds from 2002 - 2010. The ﬁsh conversion ratio (FCR, blue line) has remained
fairly constant since 2002. Permission to reprint from Norwegian Seafood Federation (FHL).
Technological advancements in the beginning of the 20th century lead to the
industrial production of vegetable oils for cooking. The production of vegetable
oils was further augmented by the use of solvent extraction which made large scale
production of vegetable oils more efﬁcient and proﬁtable (Simopoulos, 1999). The
increased availability of vegetable oils and the current public recommendation to
replace saturated fat with vegetable oil due to the cholesterol lowering and cardio-
vascular protective properties of PUFA (Kannel et al., 1964, 1971; Hegsted et al.,
1965; Keys et al., 1965; Keys and R.W., 1966; Harris et al., 2009) have caused an
imbalance in the intake of n-6 to n-3 fat. The intake of soybean oil, one of the
major dietary sources of LA, has increased dramatically in the US during the 20th
century, whereas the availability of ALA, EPA and DHA decreased in the same
period (Blasbalg et al., 2011). Technological advancements, changes in modern
agri -and aquaculture and current dietary guidelines are contributing factors in the
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shift from an evolutionary ratio of n-6 to n-3 of 1:1 to the current US ratio of 10-
20:1 (Simopoulos, 2001). Compared to the dietary changes, our genetic proﬁle
has remained fairly constant and we now live in a nutritionally environment that
is very different from which our genetic constitution was selected (Simopoulos,
1999).
2.1.1 Dietary guidelines
The US Department of Agriculture (USDA) by Wilbur Olin Atwater published
its ﬁrst dietary recommendations in 1894. Prompted by President Franklin Roo-
sevelt a National Nutrition Conference took place in 1941 which resulted in the
ﬁrst Recommended Dietary Allowances (RDA) for caloric intake and essential
nutrients to provide “standards to serve as a goal for good nutrition” (National Re-
search Council, 1943). In 1961 the American Heart Association published dietary
recommendations regarding fat and heart disease "based on the best scientiﬁc in-
formation available at the present time” stating that “the reduction or control of
fat consumption under medical supervision, with reasonable substitution of poly-
unsaturated for saturated fats, is recommended as a possible means of preventing
atherosclerosis and decreasing the risk of heart attacks and strokes” (Page et al.,
1961). The Norwegian National Board of Nutrition, established in 1946, pub-
lished its ﬁrst dietary advices in 1954 (Meltzer et al., 2004). A national comitée
led by Dr. Nicolaysen concluded in 1963 that saturated fat was a major reason for
the increase in infarct mortality and therefore recommended to reduce dietary fat
to less than 30 percent of total energy intake (Hjort, 1963).
Dietary advices have changed during the last 40 years from a reason to pro-
tect against deﬁciency diseases to prevent chronic diseases such as diabetes type
2, coronary heart disease and cancer (Meltzer et al., 2004). The primary objec-
tives for current dietary recommendations are to 1) assure primary needs 2) give
premise for good health and decrease the risk of diet-induced diseases and 3) avoid
excessive intake that may cause adverse effects. In Norway, the National Board of
Nutrition, part of the Norwegian Directorate of Health, presented updated dietary
advices in 2011. The aim of the new dietary guidelines is to promote public health
with focus on primary prevention of chronic diet-induced diseases within the adult
population in Norway (Nasjonalt Råd for Ernæring, 2011). The report recognizes
that a major part of the Norwegian population needs to adjust or change their di-
etary habits in order to achieve better public health. The guidelines recommend
increased use of vegetable oils with high level of unsaturated fat, such as rapeseed,
sunﬂower, olive and soybean oil
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PUFA requirements
An essential nutrient is needed for normal development and functions through-
out the life cycle, and must be provided by the diet. The requirement can vary
with species, gender, age and physiological and pathological challenges (Cun-
nane, 2003). Traditionally, the only fatty acids considered essential were LA and
ALA. Humans and mammals are not able to make these fatty acids de novo and are
thus dependent upon dietary intakes. Pragmatics will also include AA and DHA
as essential fatty acids since these fatty acids are not made in sufﬁcient amounts by
newborn infants to guarantee normal development (Crawford, 1993; Carlson and
Neuringer, 1999), or to sustain brain accumulation of DHA equivalent to breast-
fed infants (Cunnane et al., 2000).
A requirement should be at the minimum amount to maintain apparently nor-
mal physiology (Lands, 1992). LA and ALA requirements were set at levels that
prevented biochemical and physiological symptoms of deﬁciency (skin problems,
hair loss and growth retardation) and optimized tissue PUFA content. In the 1950-
1960s, Ralph Holman and colleagues estimated LA requirement to be 1% of di-
etary energy intake (Holman, 1960). In 1976, Cuthbertson (1976) noted that min-
imum requirements for essential fatty acids in infancy were “set far too high and
are in fact less than 0.5 en%”.
The majority of studies to determine LA requirement used diets that were
depleted in both LA and ALA, or based requirements on the level necessary to
reach a plateau of n-6 in tissues (Cunnane, 2003). In rodents, as long as minimum
quantities of dietary ALA was present (200 mg/100 g diet), dietary LA of 150
mg/100 g diet covered the minimal requirements, whereas 1200 mg/100 g diet
was required to reach a plateau of n-6 PUFA in liver (Bourre et al., 1990b). n-
3 deﬁciency exacerbate n-6 deﬁciency symptoms and higher amount of LA is
needed to correct deﬁciency symptoms when dietary ALA is absent (Greenberg
et al., 1950; Mohrhauer and Holman, 1963a). In the presence of 0.5 en% ALA,
0.5 en% LA appears to be sufﬁcient for the growing rat (Guesnet et al., 2011).
An n-6 “deﬁcient” diet (10% of LA requirement for rodents) caused no adverse
effects as long as minimum requirements of ALA were present, but decreased AA
and increased EPA and DHA in tissues compared to an n-6 adequate diet (Igarashi
et al., 2009). Therefore current LA requirements are believed to be overestimated
(Cunnane, 2003; Ailhaud et al., 2008) and cannot be determined in the absence of
dietary ALA (Cunnane, 2003).
There are no well controlled studies to establish the minimum required intake
of n-6 PUFA in healthy human adults (ISSFAL, 2004). The human requirements
for LA are based on estimates from experimental measurements. It has been sug-
gested that 1 en% LA is sufﬁcient to meet n-6 PUFA requirements in healthy
adults (Cunnane, 2003). 2 en% LA and 0.7 en% ALA are considered adequate
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for healthy human adults, although LA requirements may be higher during preg-
nancy, lactation and early development but should not exceed 3 en% (ISSFAL,
2004). EPA and DHA were traditionally not regarded as essential fatty acids and
thus no minimum requirements have been established for these fatty acids.
PUFA recommendations
Providing the minimum requirement of a nutrient to avoid deﬁciency symptoms
may not be sufﬁcient in prevention of lifestyle-related diseases resulting from an
excess intake of certain nutrients. Dietary recommendations offer quantitative
estimates of nutrient intakes applicable to healthy individuals. Intakes outside the
acceptable range increase the risk for deﬁciency and diseases due to excessive
intakes (IOM, 2006).
Despite several consensus’ and research stating the importance of lowering
dietary n-6 PUFA and increasing n-3 PUFA to achieve a healthier diet and reduce
the burden of diseases such as cardiovascular and mental illnesses (Lands, 1992,
2009; Simopoulos, 1999; ISSFAL, 2004; Hibbeln et al., 2006; Global Omega-3
Summit, 2011), most of the current n-6/PUFA recommendations are set at 5-10
en% (Table 2.1).
There is no conclusive scientiﬁc evidence with regards to the issue of a safe
upper limit of dietary n-6 PUFA but there is a controversy regarding the health
properties of a LA intake above an adequate intake of 2 en% (ISSFAL, 2004) es-
pecially related to cardiovascular disease (CVD). Several meta-analyses (Gordon,
1995; Mozaffarian et al., 2010), and reviews (Harris, 2008; Harris et al., 2009; Cz-
ernichow et al., 2010) support the protective properties of PUFA, and n-6 PUFA in
particular, in cardiovascular heart disease. The American Heart Association rec-
ommends 5-10 en% LA to improve heart health (Harris et al., 2009). Important
to remember, PUFA from the n-3 and n-6 series are chemically and nutritionally
distinct fatty acids, and are precursors of metabolites with distinct physiological
responses. The inconsistent use of PUFA makes it difﬁcult to distinguish the ef-
fect of n-6 PUFA from that of n-3 PUFA. In contrast to Mozaffarian et al. (2010),
Ramsden et al. (2010) found signiﬁcant different effect on cardiovascular disease
when separating studies using a mix of n-3 and n-6 from n-6 speciﬁc PUFA. Ran-
domized controlled trials using a mix of n-3 and n-6 PUFA signiﬁcantly reduced
the risk of non-fatal myocardial infarction and coronary heart disease (CHD). By
contrast, n-6 speciﬁc PUFA diets increased the risk of all CHD endpoints, point-
ing out the importance of distinguishing between n-3 and n-6 PUFA (Ramsden
et al., 2010).
Although not regarded essential by all, EPA and DHA deﬁciency is slowly
being recognized as detrimental to human health. Dietary recommendations of
EPA and DHA to healthy adults varies from 250 mg/day set to prevent the de-
22
Table 2.1: PUFA recommendations
n-3 PUFA
Organization Year PUFA
(en%)
n-6 PUFA
(en%)
ALA
(en%)
EPA+DHA
(g)
Norway1 2005 5 - 10 1 en%11
Japan2 2005 < 10 2.2 - 2.6 g 12
Nordic Nutrition Recommendations3 2004 313 > 1 en%
British Nutrition Foundation4 2009 6, < 10 > 1 > 0.2
Eurodiet Core Report5 2001 4 - 8 2 0.2
National Institute of Medicine6 2005 5 - 814 0.5
American Heart Association7 2009 5 - 10 1 - 4 15
American Dietetic Ass and Dietetians of Canada8 2007 3 - 10 1.2 0.5
EFSA9 2010 0.5 0.2516
ISSFAL10 2004 217 0.718 > 0.519
1 (Nasjonalt Råd for Ernæring, 2011), 2 (Ministry of Health, Labor and Welfare, Japan, 2004), 3 (NNR,
2004), 4 (BNF, 2009), 5 (Eurodiet Core Report, 2001), 6 (IOM, 2005), 7(Harris et al., 2009), 8 (Kris-
Etherton et al., 2007), 9 (EFSA, 2010), 10 (ISSFAL, 2010). 11at least 1 en% from n-3 PUFA, 12 2.2 g
for adult women and 2.6 for adult men, 13 provide some margin above minimum requirement, 14 5 en%
for women and 8 en% for men, 15 1 g for patiens with cardiovascular disease and 2-4 g for patients with
high triglycerides, 16 for healthy adults, 17 adequate intake, 18 healthy intake, 19 expected to reduce risk
for cardiovascular deaths in healthy adults. Abbreviations: EFSA European Food Safety Authority, en%
energy percent, ISSFAL International Society for the Study of Fatty Acids and Lipids, < no more than,
> at least.
velopment of cardiovascular disease (EFSA, 2010) to 2.6 g/day to maintain and
promote health and to prevent lifestyle-related diseases (Ministry of Health, La-
bor and Welfare, Japan, 2004). Norway has no speciﬁc dietary recommendations
for EPA and DHA, but recommend that at least 1 of the 5-10 en% PUFA should
be n-3 PUFA (Table 2.1). In line with several other countries and organizations
(Table 5.2 in (VKM, 2011)) Norwegians are recommended to eat 300-450 g ﬁsh
per week (of which 200 g should be fatty ﬁsh (Nasjonalt Råd for Ernæring, 2011),
whereas American guidelines recommend 8 ounces (226 g) of seafood, equivalent
to 2 servings of seafood a week (USDA, 2010). Seafood is a good source of EPA
and DHA and Norwegians and Americans are recommended to eat more seafood
(USDA, 2010; VKM, 2011).
2.1.2 Dietary n-6
The n-6 fatty acid LA is our main dietary PUFA and the precursor of arachidonic
acid (AA). LA is a signiﬁcant component of western type diets and occurs natu-
rally in seed oils and high levels can be found in vegetable oils such as safﬂower
oil (75%), sunﬂower oil (69%), soybean oil (55%) and maize oil (45%).
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The pro-adipogenic effect of linoleic acid
The adipogenic effect of dietary LA was already reported in 1966 when dietary
vegetable oil replaced saturated fat in veterans (Dayton et al., 1966). Men re-
ceiving vegetable oil had elevated serum levels of LA, increased adipose tissue
mass and they gained more weight than men on the conventional diet of saturated
fat (Dayton et al., 1966). In 1985, Cunnane et al. (1985) reported higher body
weight in mice fed evening primrose oil (72% LA) compared to mice fed cod
liver oil (16% EPA and DHA). Several studies support the ﬁndings of higher body
weight and adiposity from vegetable oils rich in LA (Ikemoto et al., 1996; Okuno
et al., 1997; Takahashi and Ide, 2000; Pellizzon et al., 2002; Massiera et al., 2003,
2010; Javadi et al., 2004; Madsen et al., 2008). An epidemiological report link
increased LA intake over the last 40 years, especially in infant feeding, to the
increased prevalence of obesity and postulate that AA-induced elevations in the
endocannabinoid 2-AG may have altered energy balance towards obesity (Ailhaud
et al., 2008). Savva et al. (2004) reported a positive association between adipose
tissue AA and BMI in overweight children.
On the other hand, lower adipose tissue accumulation has been reported in
mice fed soybean and safﬂower oil compared to saturated fat (Shimomura et al.,
1990; Takeuchi et al., 1995; Matsuo et al., 2002). The opposing effect of LA
on adipose tissue development have been explained by diet-induced differences
in cyclic AMP (cAMP) levels, which can be altered by the carbohydrate/protein
ratio (Madsen et al., 2008).
2.1.3 Dietary n-3
The n-3 fatty acid ALA, found in vegetable oils, is the precursor of EPA and
DHA, occurring naturally in marine sources. The majority of beneﬁcial effects of
n-3 PUFA in terms of cardiovascular protection and mental health are attributed
to EPA and DHA.
Anti-adipogenic effect of EPA and DHA
Fatty acids of the n-3 and n-6 series are not equipotent in promoting adipose tis-
sue development (Ailhaud et al., 2006) and they affect gene expression of white
and brown adipose tissue differently (Takahashi and Ide, 2000). Fish oil upreg-
ulate uncoupling protein 1 (UCP1) in brown adipose tissue (Takahashi and Ide,
2000) which induce thermogenesis (Cannon and Nedergaard, 2004), downregu-
late the expression of the sterol regulatory element-binding protein-1c (SREBP-
1c) in liver which is responsible for regulating genes involved in de novo lipo-
genesis (Kim et al., 1999, 2002; Tandy et al., 2009; Piscitelli et al., 2011) and
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upregulate intestinal lipid metabolism (Mori et al., 2007). Krill oil is superior
to ﬁsh oil in elevating the levels of palmitoylethanolamide (PEA) an activator of
the peroxisome proliferator-activated receptor α (PPARα) (Piscitelli et al., 2011).
Activation of PPARα and down-regulation of SREBP-1c mRNA in liver is be-
lieved to be related to the hypolipidemic effect of ﬁsh oil in a high fat diet (Kim
et al., 1999).
There is a general notion that ﬁsh oil rich in EPA and DHA limits diet-induced
obesity in rodents (Belzung et al., 1993; Hill et al., 1993). An effect that is asso-
ciated with reduced tissue levels of AA -PL (Cunnane et al., 1985). EPA and
DHA from ﬁsh oils are also associated with weight reduction in humans. Epi-
demiological studies report that ﬁsh consumption within a healthy eating pattern
is associated with lower body weight (Shubair et al., 2005; Schulze et al., 2006),
and dietary intervention studies support the notion that ﬁsh consumption helps to
control body weight (Mori et al., 1999; Kunesova et al., 2006; Thorsdottir et al.,
2007). Inclusion of ﬁsh or EPA and DHA supplements to calorie restricted diets
resulted in higher weight loss than an isocaloric control diet (Thorsdottir et al.,
2007) and greater reduction in BMI and hip circumference than placebo (no EPA
and DHA) or diet alone (Kunesova et al., 2006). Changing to a Mediterranean
diet lowered the ratio of n-6 to n-3 in plasma and was associated with reduced
body weight, BMI and inﬂammatory markers, and improved insulin sensitivity
and elevated adiponectin levels (Esposito et al., 2011).
Important to note, the obesogenic potential of diets rich in both n-6 and n-
3 PUFA is increased by elevating the levels of dietary carbohydrates (Ma et al.,
2011; Madsen et al., 2008), demonstrating the importance of the background diet
on the effect of dietary fat in adipose tissue development.
2.2 Linoleic acid lowering to increase tissue EPA and
DHA
The proportion of n-6 HUFA in tissue can be used as an indicator of disease risk
(Lands, 2009). Cardiovascular deaths correlate with the percent of n-6 HUFA in
tissues for populations worldwide (Lands, 2003). A tissue composition of 50% n-
3 HUFA is estimated to protect 95% of population against mental illness and car-
diovascular disorders (Hibbeln et al., 2006; Global Omega-3 Summit, 2011). As
the fatty acid composition in tissues is reﬂected by dietary fat intake, the amount
of EPA and DHA necessary to achieve 50% n-3 HUFA in tissue depend on the
dietary amount of LA (Lands et al., 1992). An intake of 4 - 8 en% LA will require
1 - 2 g of EPA and DHA daily to achieve 50% n-3 HUFA in tissues (Table 2.2).
A meal containing 100 - 200 g salmon or 600 g - 1.2 kg cod will provide 1 - 2 g
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EPA and DHA and assure 50% n-3 HUFA in a high LA diet (Lands et al., 1992;
NIFES, 2011b).
Approximately 3.1 billion people live in countries with low ﬁsh and low ALA
availability. This results in a large segment of the world’s population that is likely
to have serious consequences due to n-3 PUFA insufﬁciency (Petrova et al., 2011).
8.5 % of the population with low ﬁsh/ALA availability lives in Eastern Europe
where sunﬂower oil is the main oil used for cooking. Sunﬂower oil contain 69%
LA giving a high LA and very low ALA and DHA content in adipose tissue
(Petrova et al., 2011).
To ensure sustainability and improve the n-3 HUFA tissue composition, espe-
cially in people living in areas with low ﬁsh availability, emphasis should be on
lowering dietary LA to increase tissue EPA and DHA. The proportions of dietary
LA and ALA alter the synthesis and conversion of ALA to EPA and DHA (Bourre
et al., 1990b; Lands, 1992; Guesnet et al., 1997). In a “western” diet with high in-
take of LA, the conversion of ALA to EPA, and especially DHA, is not sufﬁcient
to sustain tissue DHA (Brenna et al., 2009). But substantial reduction in dietary
LA increases tissue EPA and DHA in both humans and animals (Clark et al., 1992;
Jensen et al., 1996; Liou et al., 2007; Igarashi et al., 2009; Novak et al., 2008; Mu-
nakata et al., 2009; Guesnet et al., 2011), and highlight the importance of lowering
dietary LA to increase tissue concentrations of EPA and DHA.
Table 2.2: PUFA intakes and n-3 HUFA in tissue
Concurrent dietary Tissue n-3 HUFA to meet
intake (en%)1 target tissue target2
% n-3
Country LA ALA AA in HUFA en%3 mg/d
Philippines 0.80 0.08 0.06 50 0.06 133
Denmark 2.23 0.33 0.09 50 0.26 578
Iceland 2.48 0.33 0.10 50 0.31 689
Colombia 3.21 0.24 0.04 50 0.30 667
UK 3.91 0.77 0.07 50 0.39 567
Nederlands 4.23 0.28 0.08 50 0.50 1111
Australia 4.71 0.49 0.07 50 0.51 1133
Italy 5.40 0.51 0.06 50 0.56 1244
Germany 5.57 0.62 0.06 50 0.57 1267
Bulgaria 7.02 0.06 0.05 50 0.73 1622
Israel 7.79 0.67 0.07 50 0.85 1889
USA 8.91 1.06 0.08 50 0.98 2178
1 Percent energy per day, 2 appears to protect 98% of the population
from disease risks, 3 based on a 2000 kcal/d diet. Abbreviations: AA
arachidonic acid, ALA α-linolenic acid, en% percent energy, HUFA
highly unsaturated fatty acids (> 20 carbon), LA linoleic acid. Adapted
and reprinted with permission from authors (Hibbeln et al., 2006).
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2.3 Dietary linoleic acid and early development of
obesity
The prevalence of overweight and obesity among youths continue to rise despite
decreasing intakes of total energy as fat (Troiano et al., 2000). Since the 1970s
the percentage of US children between 6 and 11 months of age above the 95th
percentile of the weight-for-length growth reference curve has increased (Ogden
et al., 1997). Breast milk reﬂects the dietary fat consumed by the mothers. The
content of LA in breast milk of US women has increased from 5% to 17% between
1945 and 1995 (Jensen et al., 1989; Jensen, 1996, 1999), and are considerably
higher than in breast milk of European and Australian women (Ailhaud et al.,
2006). The higher prevalence of infant adiposity emphasizes the qualitative issues
of dietary fat since it is not likely be explained by an increased energy and fat
intake or by increased sedentarity (Ailhaud et al., 2006).
In rodents, the maternal diet during gestation and lactation can have a signif-
icant impact on nutrient preference in offspring (Walker et al., 2008). Maternal
consumption of a high fat diet can program hypothalamic pathways that regu-
late feeding (Grove et al., 2005) and cause hyperphagia as adults (Sullivan et al.,
2011). Dams consuming a high fat/lard diet increased the preference to a high
fat diet in offspring whereas a high fat/ﬁsh oil maternal diet did not (Nakashima,
2008).
Adipocyte formation is an irreversible process. In humans, the proliferative
capacity of adipose precursor cells from subcutaneous adipose tissue is highest
during the ﬁrst year of life and before puberty (Massiera et al., 2003; Ailhaud
et al., 2006). Thus, an early age is a highly sensitive period during which adipose
tissue expands dramatically. Several animal studies report higher body weight,
increased fat accumulation, hyperplasia and hypertrophy of adipose tissue and el-
evated plasma leptin levels in offspring from mothers fed a high fat/high n-6 diet
compared to offspring from mothers fed high fat/high n-3 rich oils (Cleary et al.,
1999; Korotkova et al., 2002; Massiera et al., 2003; D’Asti et al., 2010). A re-
cent study demonstrate how quantity and quality of maternal dietary fat during
the perinatal period directly inﬂuences neonatal metabolism, fatty acid compo-
sition in phospholipids and sensitivity to endocannabinoid system manipulation
(D’Asti et al., 2010). Another recent study show that mice fed a “western-like”
diet of 35 en% fat containing 18 en% LA and 0.6 en% ALA for 4 generations
resulted in a gradual transgenerational increase in adiposity through hyperplasia
and hypertrophy with no signiﬁcant change in food intake. The enhanced adipos-
ity was apparent in pups at weaning and maintained in adulthood (Massiera et al.,
2010). Continuous exposure to high levels of LA also increased inﬂammatory
stimuli (Massiera et al., 2010). In humans, nonobese offspring from obese parents
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had higher C-reactive protein levels compared to offspring from one or no obese
parent, indicating that obese parents transmit a susceptibility to predispose off-
spring to systemic inﬂammation and neurohormonal activation (Lieb et al., 2009).
Changes occurring during development appear to be persistent and affect disease
outcome later in life.
2.4 The endocannabinoid system
The endocannabinoid system includes the cannabinoid receptors 1 and 2 (CB1
and CB2) and the endogenous ligands of which the two best characterized are
2-arachidonoyl-glycerol (2-AG) and N -arachidonoylethanolamine (anandamide
or AEA). The endocannabinoids are endogenous marijuana-like lipid mediators
synthesized on demand in animals, including humans, from the pool of 20 carbon
n-6 fatty acids present in membrane phospholipids (Wang and Ueda, 2009).
The endocannabinoid system was discovered in the 1960s when the major psy-
choactive component of Cannabis sativa and marijuana Δ9 -tetrahydrocannabinol
(Δ9 -THC) was identiﬁed (Mechoulam and Gaoni, 1967). The CB1 receptor, one
of the most abundant G-protein-coupled receptors in the central nervous system,
was not identiﬁed until 1988 (Devane et al., 1988). The ﬁrst endogenous agonist
for the cannabinoid receptor to be discovered was anandamide named after the
Sanskrit word for “bliss” (Devane and Axelrod, 1994), followed by the identiﬁ-
cation of 2-AG in 1995 (Mechoulam et al., 1995; Sugiura et al., 1995). Several
cannabinoid analogs have been synthesized (Howlett et al., 2004). Synthetic Δ9-
THC (dronabinol) is approved for use in the USA to treat nausea and vomiting in
cancer chemotherapy, and to stimulate appetite in AIDS wasting syndromes (Me-
choulam and Hanu, 2001). The ﬁrst speciﬁc antagonist for the CB1 receptor was
SR141716 (rimonabant) which proved to be effective in reducing weight gain and
improve cardiovascular risk factors (Després et al., 2005; Van Gaal et al., 2005;
Christensen et al., 2007; Christopoulou and Kiortsis, 2011).
The presence of the cannabinergic system in most animal systems, and the
high degree of conservation of the endocannabinoid system components (Elph-
ick and Egertova, 2001) points out the importance of the endocannabinoid system
in the control of basic physiological activities such as feeding and energy home-
ostasis (Yamaguchi et al., 1996; Sepe et al., 1998; De Petrocellis et al., 1999;
Soderstrom et al., 2004; Valenti et al., 2005). However, the presence of the endo-
cannabinoids should not in itself be interpreted as evidence that they necessarily
function as part of an endocannabinoid system. Anandamide is found to be present
in chocolate (di Tomaso et al., 1996) but it is not believed that cannabinoid sig-
naling pathways exist in the cocoa bean (Elphick and Egertova, 2001).
In terms of evolution, nature has selected the endocannabinoid system whose
28
main physiological function appears to reorientate energy balance towards energy
storage (Piazza et al., 2007). The importance of the endocannabinoid system was
more apparent 4 million years ago when humans lived as hunter/gatherers with
unstable food supply. People ate when hungry to counteract the decrease in en-
dogenous nutrient levels. The introduction of agriculture provided more stable
conditions and has along with recent technological advances in food preservation
shifted the nutritional environment to an excess of food supply and people now eat
when food is available. Thus an excessive food supply and an overactivation of
the CB1 receptor can lead to overeating and an orientation of metabolism towards
excessive energy storage (Piazza et al., 2007).
2.4.1 Endocannabinoids and appetite
Hyperphagia following cannabis intoxication is a widely accepted phenomenon
known as the “the munchies”. The appetite stimulant properties of marijuana
was recorded as early as 300 AD (Abel, 1971). In 1976, Greenberg et al. (1976)
reported increased food intake and weight gain in men smoking marihuana for
21 days (Figure 2.2). Food intake stabilized to pre-experimental levels after 7
days of smoking, whereas body weight continued to increase independent of food
intake. The ability of cannabinoid activation to affect appetite appears to be tran-
sient whereas the metabolic effects remain active longer (Greenberg et al., 1976;
Colombo et al., 1998).
Central stimulation of the CB1 receptor by 2-AG and anandamide increases
hunger-induced elevation in food intake, and decrease in satiety (Williams and
Kirkham, 1999; Kirkham et al., 2002). The endocannabinoid system controls food
intake at two levels; 1) it reinforces the motivation to ﬁnd and consume foods with
high incentive value, and 2) induces appetite by regulating levels and/or action of
orexigenic and anorectic mediators (Di Marzo and Matias, 2005). The hyper-
phagic properties of endocannabinoids were reported in 1999 when anandamide
injected peripherally stimulated overeating in satiated rats, an effect that was at-
tenuated by selectively blocking the CB1 receptor by SR141716 (Williams and
Kirkham, 1999). Anandamide caused a modest hyperphagia that appeared over a
longer time course compared to Δ9 -THC (Williams and Kirkham, 1999). Injec-
tion of 2-AG into the nucleus accumbens shell, an area of the brain associated with
appetite stimulation, induced eating in rats (Kirkham et al., 2002). The increase in
food intake from 2-AG injections was prevented by pre-treatment with SR141716,
while the CB2 antagonist SR144258 had no effect. Thus demonstrating that the
hyperphagic properties of anandamide and 2-AG are speciﬁcally mediated by cen-
tral CB1 receptors (Williams and Kirkham, 1999; Kirkham et al., 2002).
Endocannabinoid activity seems to represent an ampliﬁcation, or potentiation,
associated with the normal episodic pattern of meal-taking in rats, thereby in-
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creasing the size of meals (Kirkham and Williams, 2001). Endocannabinoid lev-
els decline once eating is initiated, indicating that endocannabinoid activity is not
needed for maintenance of food intake (Kirkham et al., 2002). The functional re-
lationship between endocannabinoids and dopaminergic activity in the brain may
be important for the incentive value and hedonic evaluation of food (Williams
and Kirkham, 2002). The incentive value of a food is acquired through expe-
rience (Balleine and Dickinson, 1998). Preference and hunger state are factors
that contribute to the incentive value of a food (Balleine and Dickinson, 1998).
Endocannabinoids are believed to increase the incentive value of food and to be
implicated in the processes underlying the motivation to eat, and not primarily
involved in food reward during eating (Kirkham and Williams, 2001). Leptin,
released by adipocytes, may act through down-regulation of hypothalamic endo-
cannabinoid levels (Di Marzo and Matias, 2005), which may be the mechanism
of which endocannabinoids reduce the general incentive value of food and restrict
feeding.
Central endocannabinoid signaling seems to be important in regulating energy
homeostasis. An elevated endocannabinoid tone in brain is sufﬁcient to induce
insulin resistance in liver, and high endocannabinoid levels in brain can impair
hypothalamic insulin action in liver and adipose tissue (O’Hare et al., 2011).
2.4.2 Endocannabinoids and energy homeostasis
Genetic and chronic pharmacological impairment of the CB1 receptor have demon-
strated the role of the endocannabinoid system in energy homeostasis through
inhibition of food intake and reduction in body weight occurring independent
of energy intake (Cota et al., 2003; Ravinet Trillou et al., 2003; Poirier et al.,
2005)(Figure 2.2).
An early endocannabinoid-mediated increase in de novo lipogenesis appears
to be a critical component in diet-induced obesity (Osei-Hyiaman et al., 2005). In
liver, dietary LA and pharmacological stimulation of the CB1 receptor increase de
novo fatty acid synthesis through the induction of the lipogenic transcription factor
SREBP-1c and its target enzymes fatty acid synthase (FAS) and acetyl-coenzyme-
A carboxylase-1 (ACC1), which was blunted by CB1 antagonist (SR141716) and
absent in CB1 knock-out mice (Osei-Hyiaman et al., 2005). Mice with a speciﬁc
knock-out of liver CB1 receptors develop a similar degree of obesity as wild-
type mice but are not insulin and leptin resistant and have less hyperglycemia
and dyslipidemia compared to wild-type mice (Osei-Hyiaman et al., 2008). This
ﬁnding delineate the contribution of the endocannabinoid system/CB1 receptor in
liver to speciﬁc components of the metabolic syndrome induced in mice fed a high
fat diet (Osei-Hyiaman et al., 2008).
In adipose tissue, the endocannabinoid system is up-regulated immediately
30
		

	

	
	
	 !"#$%
 	 
&
	

'(
	)
(		
*+	,
	
		
	
(	

-.
.
	

Figure 2.2: Endocannabinoids, CB1 action and energy metabolism. Activation of the CB1 re-
ceptor centrally and peripherally, favors metabolic processes that stimulate appetite and increase
food intake, increase fatty acid synthesis and increase adipose tissue development. Overactivity of
CB1 stimulation may therefore lead to obesity and associated metabolic disorders. Pharmacolog-
ical blocking of the CB1 receptor by the selective antagonist rimonabant reduces weight gain by
preventing preadipocyte cell proliferation, inducing energy expenditure and affecting adiponectin
secretion. Abbreviations: BAT brown adipose tissue, cAMP cyclic AMP, CB1 cannabinoid re-
ceptor 1, HU210 cannabinoid receptor agonist, UCP1 uncoupling protein 1, WAT white adipose
tissue.
before adipocyte differentiation, possibly inducing differentiation and lipogene-
sis via CB1 mediated inhibition of cAMP formation (Matias et al., 2006b). The
mature adipocytes produce leptin which may act to turn off endocannabinoid ac-
tion (Matias et al., 2006b) (Figure 2.2). Pharmacologically blocking the CB1
receptor by rimonabant modulates the expression of genes involved in matura-
tion of adipocytes (Jbilo et al., 2005), inhibits preadipocyte cell proliferation and
prevents lipid accumulation in adipocytes (Gary-Bobo et al., 2006), increases the
expression of UCP1 by inducing transdifferentiation of white adipocytes to a ther-
mogenic brown phenotype (Perwitz et al., 2010) and is implicated in the control of
adiponectin secretion (Bensaid et al., 2003; Gary-Bobo et al., 2006; Matias et al.,
2006b). In contrast to pharmacological blocking of the CB1 receptor, chronic
overactivation by the CB1 agonist HU210 reduced the expression of adiponectin
(Matias et al., 2006b). Adiponectin is a hormone secreted from the adipose tissue
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that can induce fatty acid oxidation and cause weight reduction (Fruebis et al.,
2001), reverse insulin resistance and decrease hyperinsulinemia (Yamauchi et al.,
2001b), improve insulin sensitivity and decrease triglyceride storage in liver and
muscle (Yamauchi et al., 2001b) and has anti-inﬂammatory and anti-atherogenic
properties (Diez and Iglesias, 2003). Adiponectin levels are decreased in serum of
humans with insulin resistance, obesity, type II diabetes mellitus and heart disease
(Diez and Iglesias, 2003; Hotta et al., 2000).
2.4.3 Dietary fat and endocannabinoid levels
The endocannabinoids anandamide and 2-AG are endogenous lipid derivates of
the n-6 fatty acid arachidonic acid in the sn-1 and sn-2 position of phospholipids
(AA -PL) respectively (Banni and Di Marzo, 2010a). Because humans cannot
synthesize AA de novo tissue concentrations in phospholipids are dependent upon
1) dietary intakes of the AA, 2) the AA precursor LA and 3) content of compet-
ing fatty acids such as EPA and DHA (Mohrhauer and Holman, 1963b; Bourre
et al., 1990a; Cunnane et al., 1985; Lands et al., 1992). It has therefore been
hypothesized that an excess of dietary n-6 or intakes of n-3 fatty acids alter the
availability of biosynthetic precursors and subsequently tissue concentrations of
endocannabinoids (Matias et al., 2008b; Batetta et al., 2009; Banni and Di Marzo,
2010b; Piscitelli et al., 2011). Figure 2.3 indicates how the shift in available seed
oils changes the estimated tissue composition of n-6 HUFA described in Blasbalg
et al. (2011), and inﬂuences the precursor level for endocannabinoid synthesis.
Dietary fatty acids can modulate and cause profound tissue-speciﬁc changes
on endocannabinoid levels after short-term (Artmann et al., 2008; Wood et al.,
2010) and long-term exposure (Osei-Hyiaman et al., 2005; Matias et al., 2008b;
Starowicz et al., 2008; Piscitelli et al., 2011). In vivo and in vitro studies have
demonstrated that n-3 deﬁciency and dietary AA increase (Berger et al., 2001; Art-
mann et al., 2008; Matias et al., 2008a), whereas dietary EPA and DHA decrease
endocannabinoid levels (Watanabe et al., 2003; Artmann et al., 2008; Batetta et al.,
2009; Di Marzo et al., 2010; Wood et al., 2010). There are indications that physi-
ological functions and pathological conditions involving endocannabinoids could
be correspondingly modiﬁed by the manipulation of dietary fatty acids, such as a
beneﬁcial effect of n-3 PUFA and an exacerbating effect of n-6 PUFA in obesity,
dyslipidemia and insulin resistance (Banni and Di Marzo, 2010b).
2.4.4 Hyperactivity of the endocannabinoid system
The body’s ability to keep a relatively stable body weight indicates that energy
balance is controlled in a way to maintain constancy of total body energy stores.
Multiple signals and systems are involved in maintaining energy homeostasis. A
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Figure 2.3: The endocannabinoids 2-AG and anandamide are synthesized on demand from AA
in membrane phospholipids (AA-PL). AA in the phospholipid precursor pool can be elevated by
dietary LA or diminished by consumption of n-3 fatty acids notably EPA and DHA. Activation
of the CB receptors by 2-AG and anandamide centrally and peripherally affects satiety and fat
storage. The ﬁgure indicates the hypothesis that these shift in diet, and resulting endocannabinoid
levels, may contribute to the increasing prevalence of obesity in the US during the 20th century.
sustained hyperactivity of the endocannabinoid system is believed to have a causal
role in obesity and to be one of the underlying factors in the development of hy-
perglycemia, dyslipidemia, ectopic fat accumulation, insulin resistance and type
2 diabetes (Di Marzo, 2008; Kunos et al., 2008).
The hypothalamus, known as the brains “hunger center”, is an important re-
gion the control of satiety and hunger, and in maintaining energy homeostasis.
The hypothalamus receives and synthesizes hormonal stimuli to coordinate the
central nervous system to the endocrine system. Leptin is a hormone that signals
nutritional status and modulates food intake and energy balance by suppressing
appetite and stimulating lipid oxidation. In normal animals leptin is involved in
the up-regulation of anorectic signals (neuropeptides) and down-regulate orexi-
genic signals expressed in the hypothalamus (Friedman and Halaas, 1998). In
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obese subjects the actions of leptin are absent or inefﬁcient resulting in leptin re-
sistance (Friedman and Halaas, 1998) which may elevate endocannabinoid levels
in hypothalamus (Di Marzo et al., 2001). Higher hypothalamic endocannabinoid
levels in leptin deﬁcient subjects may lead to a chronic state of what has been de-
scribed as perceived starvation (Friedman and Halaas, 1998). Thus the hyperpha-
gia exhibited by genetically obese rodents is believed to arise from a motivational
state that mimics the natural hunger generated by food deprivation (Kirkham et al.,
2002).
Mice with diet-induced obesity display elevated tissue endocannabinoid levels
compared to lean controls and CB1 knock-out mice (Osei-Hyiaman et al., 2005;
Matias et al., 2006a; Starowicz et al., 2008). Overactivity of the endocannabinoid
system in pancreas is believed to underlie the hyperinsulinemia that characterizes
obesity by causing β -cell hypertrophy and damage that eventually might lead to
the development of type 2 diabetes (Matias et al., 2006b). Insulin is an anabolic
hormone that stimulates adipocyte differentiation and adipose tissue expansion
(Madsen et al., 2010). In continued presence of insulin adipocytes becomes hy-
pertrophic and have high levels of CB1 receptors and 2-AG (Matias et al., 2006b).
In a state of insulin resistance, more insulin is required to promote glucose uptake
by peripheral tissues, and insulin deﬁciency disrupts the regulation of glucose
production in the liver, glucose uptake in the muscle and release of fatty acid
from adipose tissue (Esposito et al., 2008; Di Marzo et al., 2011). Insulin resis-
tant adipocytes loose their ability to regulate endocannabinoid metabolism (D’Eon
et al., 2008) and are thus unable to decrease intracellular endocannabinoid pool in
response to insulin stimulation (D’Eon et al., 2008; Di Marzo et al., 2009b).
Endocannabinoid signaling seems to be upregulated in obese humans and
in subjects with high visceral adiposity and hyperglycemia (Engeli et al., 2005;
Bluher et al., 2006; Matias et al., 2006b; Pagano et al., 2007; Di Marzo et al.,
2009b). Plasma endocannabinoid levels in obese men correlate with changes in
visceral adipose tissue and metabolic risk factors (Di Marzo et al., 2009a), and
high circulating levels of 2-AG are in direct relationship to intra-abdominal adi-
posity (Bluher et al., 2006; Cote et al., 2007). Endocannabinoids are local media-
tors therefore the higher circulating levels of endocannabinoids observed in obese
subjects are most likely a “spill-over” effect from excessive levels in peripheral
tissues (Di Marzo et al., 2011). It has been speculated that an overactivity of the
endocannabinoid system in some adipose tissue depots contributes to lower levels
of adiponectin observed in obesity and hence to insulin resistance and atheroscle-
rosis (Di Marzo et al., 2011). By contrast, a lower endocannabinoid tone in subcu-
taneous versus visceral fat, as seen in obese patients with type 2 diabetes (Annuzzi
et al., 2010), may eventually contribute to excessive accumulation of visceral fat at
the expense of the more “beneﬁcial” subcutaneous depots (Di Marzo et al., 2011).
The potential causes and metabolic responses of endocannabinoid overactivity is
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described in Figure 2.4.
Growing evidence of upregulated endocannabinoid signaling in obesity lead
pharmaceutical companies to develop CB1 receptor antagonists. In 2006, the
European Medicines Agency approved rimonabant, a CB1 receptor inverse ago-
nist, following impressive clinical trial results in both obese and diabetic patients.
Speciﬁcally, placebo-controlled trials demonstrated considerable weight-loss and
signiﬁcant improvements in waist circumference, high density lipoprotein (HDL)-
cholesterol, triglycerides, inﬂammatory markers, blood pressure, fasting glucose
and fasting insulin (Després et al., 2005; Van Gaal et al., 2005; Christopoulou and
Kiortsis, 2011). In 2008, however, rimonabant was pulled from the market due
to serious psychiatric side effects, including suicide risk (Christensen et al., 2007;
Christopoulou and Kiortsis, 2011). Because pharmacological blockade of the CB1
receptor is effective in treating obesity and related metabolic derangements, a di-
etary approach to diminish endocannabinoid hyperactivity may represent a safer
alternative to pharmaceuticals. Addressing an underlying cause of endocannabi-
noid overactivation may have widespread beneﬁcial public health implications
related to obesity and metabolic syndrome.
Figure 2.4: Overactivity of the endocannabinoid system. Potential causes of endocannabinoid
hyperactivity in peripheral tissues and the consequences on metabolic risk factors. Abbreviations:
EC endocannabinoid FFA free fatty acids, HDL high density lipoprotein, T2D type 2 diabetes, TG
triglycerides. Permission to reprint from authors (Di Marzo et al., 2011).
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2.5 Aims
Efforts and courage are not enough without purpose and direc-
tion. - John F. Kennedy
We aimed to investigate if elevating a single molecular species in the diet, LA,
an essential n-6 fatty acid and the precursor of arachidonic acid, the backbone of
endocannabinoids could cause endocannabinoid hyperactivity and induce obesity.
We postulate that by addressing an underlying cause of endocannabinoid hyper-
activity using a dietary approach, we may ﬁnd a safe and viable alternative for
decreasing the development of obesity.
The overall aims of the PhD were to:
• Compare the effect of excessive endocannabinoid activity from high dietary
intake of LA in different levels of dietary fat (low - medium and high fat
diets).
• Investigate the metabolic effect of different time points of exposure to di-
etary LA - prenatally versus adulthood.
• Study the endocannabinoid response to dietary LA in Atlantic salmon and
mice - and investigate the metabolic effect in mice fed Atlantic salmon con-
taining different levels of LA.
The speciﬁc objectives of the PhD were to determine if elevating dietary LA from
1 en% to 8 en%:
• Increases arachidonic acid and lowers EPA and DHA in tissue phospho-
lipids.
• Elevates endocannabinoid system activity.
• Affects food intake and feed efﬁciency.
• Induces obesity.
• Affects adipose tissue morphology.
• Increase adipose tissue inﬂammation.
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Chapter 3
Summary of Results
Dis-moi ce que tu manges, je te dirai ce que tu es1.
- Brillat-Savarin, 1825
Paper I
Dietary linoleic acid elevates endogenous 2-AG and anandamide inducing
obesity.
1. Design
C57Bl/6 mice were exposed to diets of 35 en% fat and 60 en% fat
containing 1 en% LA, 8 en% LA and 8 en% LA + 1 en% EPA/DHA
from the last week of gestation, through lactation and for 14 weeks
after weaning.
2. Major ﬁndings
• There is a strong ecological relationship between human consumption
of the major dietary sources of LA (soybean oil, poultry and shorten-
ing) and the increasing prevalence of obesity in the US during the 20th
century.
• 8 en% LA in a high fat diet increased food intake.
• 8 en% LA increased adiposity (Figure 3.1).
• 8 en% LA increased tissue AA -PL and induced hyperactivity of the
endocannabinoid system by elevating 2-AG and anandamide in mice
liver (Figure 3.2).
1Tell me what you eat, and I will tell you what you are.
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• Reducing dietary LA to 1 en% elevated tissue EPA and DHA (Figure
3.2), and prevented the development of obesity normally induced by a
high fat diet (Figure 3.1(b)).
• Supplementing the 8 en% LA diets with 1 en% EPA + DHA prevented
the elevation of tissue AA -PL and endocannabinoid levels (Figure
3.2), and reversed the adipogenic effect of the 8 en% LA diets (Figure
3.1).
3. Conclusion
Dietary LA of 8 en% increased tissue AA -PL, subsequently elevat-
ing 2-AG and anandamide associated with the development of diet-
induced obesity. The adipogenic effect of LA can be prevented by
consuming sufﬁcient EPA and DHA to reduce the AA -PL pool and
normalize endocannabinoid tone.
(a) Medium fat (b) High fat
Figure 3.1: Dietary LA induces obesity. Dietary LA increases adiposity in mice fed (a) medium
fat diets (35 en% fat) and (b) high fat diets (60 en% fat). In each photo, mice to the left were fed
1 en% LA, mice in the middle were fed 8 en% LA and mice to the right were fed 8 en% LA + 1
en% EPA/DHA.
Paper II
Dietary linoleic acid elevates the endocannabinoids 2-AG and anandamide
and induces weight gain and inﬂammation in mice fed a low fat diet.
1. Design
C57Bl/6 mice were exposed to diets of 12.5 en% and 35 en% fat con-
taining 1 en% LA and 8 en% LA for 16 weeks from 6 weeks of age.
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Figure 3.2: Dietary LA increases AA and endocannabinoid activity and decreases EPA and
DHA in liver of mice and salmon. Selective elevation of dietary LA elevates LA -PL (A), AA -PL
(B) and 2-AG (C) and anandamide (D) in liver. Compared to 8 en% LA, diets of 1 en% LA allow
endogenous accretion of EPA (E) and DHA (F). The fatty acids in salmon are presented as amount
of total fat. Open bars represent low fat diets (12.5 en%), coarse bars medium fat diets (35 en%),
vertical lines high fat diets (60 en%) and dotted bars Atlantic salmon. Bar colors represent light
gray 1 en% diets, gray 8 en% LA and dark gray 8 en% LA + 1 en% EPA/DHA. Abbreviations:
FO mice fed ﬁsh oil (FO) salmon, HF high fat, LA linoleic acid, LF low fat diet, MF medium fat,
PL phospholipid, SO mice fed soybean oil (SO) salmon. Statistical differences are described in
individual papers. 39
2. Major ﬁndings
• Dietary LA of 8 en% increased tissue AA -PL and elevated endo-
cannabinoid activity by elevating 2-AG and anandamide in liver (Fig-
ure 3.2).
• 8 en% induced weight gain in a low fat diet (Figure 3.3).
• 8 en% LA elevated adipocyte size and adipose tissue inﬂammation.
3. Conclusion
Increasing dietary LA from 1 en% to 8 en% with a subsequent eleva-
tion in liver endocannabinoid levels may increase the risk of develop-
ing obesity and associated metabolic complications also in low a fat
diet.
Paper III
Dietary linoleic acid elevates endogenous 2-AG and anandamide in Atlantic
salmon (Salmo salar L.) and mice, and induces weight gain and inﬂammation
in mice.
1. Design
Atlantic salmon (340 g) were fed diets with ﬁsh oil or soybean oil for
6 months. C57Bl/6 mice, 6 weeks of age, were fed diets of 35 en% fat
based on ﬁllets from Atlantic salmon raised on ﬁsh oil or soybean oil
for 16 weeks.
2. Major ﬁndings
• Replacing ﬁsh oil with soybean oil in feed for Atlantic salmon in-
creased liver AA and endocannabinoid levels (Figure 3.2) and elevated
liver lipids in Atlantic salmon.
• 8 en% LA in a SO salmon diet elevated AA -PL and endocannabinoids
in mice liver (Figure 3.2).
• The SO salmon diet caused higher weight gain, increased adipocyte
cell size and caused higher adipose tissue inﬂammation in mice.
3. Conclusion
Dietary LA of 8 en% elevated endocannabinoid levels similarly in
liver of Atlantic salmon and mice. In mice, high dietary intakes of
salmon fed soybean oil increased weight gain and counteracted the
anti-inﬂammatory properties of EPA and DHA.
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Figure 3.3: Weekly weight gain. Mice in Paper I were exposed to diets for 14 weeks after
weaning (start) and for 16 weeks from 6 weeks of age (start) in Paper II and III. Abbreviations:
FO mice fed ﬁsh oil (FO) salmon, HF high fat (60 en%), LA linoleic acid, LF low fat diet (12.5
en%), MF medium fat (35 en%), SO mice fed soybean oil (SO) salmon, 1LA 1en% LA, 8LA 8
en% LA, 1EPA/DHA 1 en% EPA+DHA. Statistical differences are described in individual papers.
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Chapter 4
Discussion
Now this is not the end. It is not even the beginning of the end. But it is,
perhaps, the end of the beginning. - Sir Winston Churchill, November, 1942
4.1 Linoleic acid and the prevalence of obesity
We found a positive correlation between soybean oil, shortening and poultry, the
major dietary sources of LA, and the rise in obesity in the US during the 20th
century (Paper I). Data on the apparent soybean oil consumption is robustly as-
sociated with adipose concentrations of PUFA across 11 countries (Petrova et al.,
2011) and consistent with an epidemiological report linking increased intake of
LA to the increased prevalence of obesity (Ailhaud et al., 2008) suggesting that
AA-induced elevations in the endocannabinoid 2-AG may have altered energy
balance towards obesity (Ailhaud et al., 2008). Also, adipose tissue AA and BMI
were associated with overweight status in children. (Savva et al., 2004).
Sugar was weakly correlated with the prevalence of obesity. In contrast, changes
in total energy consumption and total fat consumption were not signiﬁcantly cor-
related with the increasing rates of obesity (Paper I). A shift from physical labor
occupations including farmers, farm laborers and laborers was negatively corre-
lated with the prevalence of obesity. We note that the shift away from physical
labor occupations is likely to be a signiﬁcant factor, however the increasing preva-
lence of obesity is also found separately within physical and non-physical labor
occupations (Caban et al., 2005). This ecological examination was not intended
to test for causality, but permitted the design of an animal model which isolated
LA as an independent variable and modeled differences in LA intake comparing
consumption at the beginning and the end of the 20th century.
4.2 Dietary fat, endocannabinoids and energymetabolism
4.2.1 Dietary fat and endocannabinoid levels
The aim this thesis was to provide a dietary approach in which decreasing sub-
strate availability for endocannabinoid synthesis could reduce hyperactivity of the
endocannabinoid system and improve metabolic functions associated with obe-
sity. Dietary inﬂuence of the endocannabinoid system is a new ﬁeld of research.
The current understanding of the endocannabinoid system in energy homeostasis
is mainly generated from pharmacological stimulation of the CB1 receptor and
the use of knock-out mice lacking the CB1 receptor (CB-/-). Several studies have
demonstrated that dietary n-6 and n-3 PUFA inﬂuence endocannabinoid levels
(Berger et al., 2001; Watanabe et al., 2003; Matias et al., 2006b; Artmann et al.,
2008; Di Marzo et al., 2010; Wood et al., 2010; Piscitelli et al., 2011) and affect
energy metabolism (Matias et al., 2006a, 2008a; Starowicz et al., 2008).
Dietary n-6 increases endocannabinoid levels
The work presented here is the ﬁrst to demonstrate the critical importance of di-
etary LA to tissue AA -PL concentrations to endocannabinoid hyperactivity, pre-
viously proposed by others (Matias et al., 2008b; Batetta et al., 2009; Piscitelli
et al., 2011; Banni and Di Marzo, 2010a). We show that increasing dietary LA
from 1 to 8 en% signiﬁcantly increased AA in the phospholipid pool subsequently
elevating liver 2-AG (50% Paper I, II) and anandamide (30-40% Paper I and II).
The highest increase in liver 2-AG and anandamide was found in mice fed a high
fat diet containing 8 en% LA (68% and 57% respectively, Paper I, Figure 3.2).
Artmann et al. (2008) did not ﬁnd elevated endocannabinoid levels from a diet
with high level of LA, however the short term exposure of one week did not allow
adequate time for the alteration of the AA -PL precursor pool.
Dietary LA of 8 en% elevated endocannabinoid levels centrally and peripher-
ally despite higher circulating leptin levels (Paper I, II and III). The expression of
leptin mRNA in adipose tissue (Paper I, Supplementary) was not affected by di-
etary LA suggesting that mice fed 8 en% LA were leptin resistent (Paper I) similar
to what is observed in obese subjects (Friedman and Halaas, 1998). Under nor-
mal circumstances leptin exerts a negative control of endocannabinoid levels in
hypothalamus (Di Marzo and Matias, 2005) and adipocytes (Matias et al., 2006b;
O’Hare et al., 2011). In an obese state, defective leptin signaling is associated
with elevated endocannabinoid levels (Di Marzo and Matias, 2005). Leptin is se-
creted from adipose tissue, thus higher circulating levels of leptin may reﬂect an
increased adipose tissue mass (Paper I). Although not obese, mice fed 8 en% LA
in low fat and medium fat diets displayed elevated leptin levels (61% and 54%
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respectively) compared to 1 en% LA (Paper II, Table 3.2) indicating that leptin
resistance may occur independent of obesity.
Dietary EPA and DHA decrease endocannabinoid levels
In our studies, tissue levels of AA -PL seems to be an important determinant
of endocannabinoid levels (Figure 3.2). Supplementing 8 en% LA diets with 1
en% EPA/DHA prevented the elevation in tissue AA -PL and liver anandamide
observed in mice fed 8 en% LA diets (Paper I). Mice fed dietary salmon (2-3
en% EPA and DHA) had the lowest liver levels of 2-AG and anandamide (Paper
III, Figure 3.2). Our results support previous studies reporting decreased endo-
cannabinoid levels from dietary long-chain n-3 fatty acids (Watanabe et al., 2003;
Artmann et al., 2008; Di Marzo et al., 2010; Wood et al., 2010; Piscitelli et al.,
2011).
The differential effect of EPA/DHA on 2-AG and anandamide levels in liver
and brain may result from the different origin of 2-AG and anandamide in the
phospholipid. Anandamide is derived from AA esteriﬁed in the sn-1 position,
whereas 2-AG is derived from AA in the sn-2 position (Banni and Di Marzo,
2010a). In vitro, the amount of AA esteriﬁed in the sn-2 position of adipocyte
phospholipids determined the amount of 2-AG (Matias et al., 2008a). ALA and
DHA affected 2-AG levels the same way as they decreased AA in the sn-2 posi-
tion (Matias et al., 2008a). Dietary fatty acids can alter endocannabinoids without
affecting AA -PL (Berger et al., 2001; Batetta et al., 2009; Di Marzo et al., 2010;
Wood et al., 2010). The exact mechanism of how dietary fatty acids alter brain
endocannabinoid levels is not clear. The dietary n-3 PUFA status seems to be
an important factor to inﬂuence brain endocannabinoid levels (Watanabe et al.,
2003). Deﬁciency of n-3 PUFA elevated 2-AG without affecting brain AA -PL,
whereas n-3 PUFA supplementation reduced brain AA -PL and 2-AG, suggest-
ing that DHA exhibit inhibitory properties on 2-AG synthesis in brain (Watanabe
et al., 2003). Krill oil appears to be superior to ﬁsh oil in lowering 2-AG levels
(Di Marzo et al., 2010; Banni et al., 2011; Piscitelli et al., 2011), indicating that
the structural form of n-3 PUFA also inﬂuences endocannabinoid levels (Di Marzo
et al., 2010; Banni et al., 2011).
4.2.2 Endocannabinoids and energy homeostasis
The role of cannabinoid receptor activation in energy homeostasis is summarized
in Figure 4.1.
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Figure 4.1: Cannabinoid receptor activation and energy metabolism. Activation of the cannabi-
noid receptors (CB1 and CB2) both centrally and peripherally, favors metabolic processes that
stimulate appetite, increase food intake, activates fat storage pathways, promote adipocyte inﬂam-
mation, and down regulates catabolism resulting in adipose accretion.
4.2.3 Central effects of endocannabinoid activation
Here we show that long-term exposure to 8 en% LA resulted in a persistent eleva-
tion in brain endocannabinoid levels (Figure 4.2). Long-term exposure of 8 en%
LA elevated n-6 HUFA in hypothalamus thereby increasing the precursor avail-
ability for endocannabinoid production consequently elevating 2-AG and anan-
damide in the thalamus/hippocampal region1.
Increasing dietary LA from 1 en% to 8 en% resulted in a similar increase
2-AG and anandamide concentrations in the thalamus/hippocampal region of pre-
natally exposed mice (Paper I) and cerebral cortex2 of mice exposed from adult-
hood (Paper II and III, Figure 4.2). Mice fed 8 en% LA in a high fat diet had
the highest increase in brain levels of 2-AG (22%) and anandamide (23%, Paper
I), together with mice fed SO salmon (24% increase in anandamide compared to
FO salmon diet, Paper III). In accordance with previous studies (Watanabe et al.,
2003; Di Marzo et al., 2010; Wood et al., 2010), supplementation of EPA and
DHA decreased brain levels of 2-AG (P < 0.013 - 0.05, Paper I) with no effect on
brain anandamide (Figure 4.2). The low amount of fat in the low fat diets was not
sufﬁcient to inﬂuence brain levels of 2-AG and anandamide (Paper II).
Our results show that duration of exposure and amount of dietary fatty acids
appears to be important factors in regards to brain 2-AG and anandamide concen-
trations. The adult brain is less susceptible to dietary manipulation than the young
brain (Rapoport et al., 2007; DeMar et al., 2008), and retain a relatively stable
1There was not enough hypothalamus tissue left after fatty acid analysis to accurately measure
endocannabinoid levels.
2The brain was cut in half at the time of sacriﬁce which made it difﬁcult to dissect out hypotha-
lamus or the thalamus/hippocampus region.
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(b) AEA in brain
Paper 2-AG (%) AEA (%)
I 11 14
II 9 9
III 12 24
(c) % increase in brain 2-AG and
AEA
Figure 4.2: Dietary LA increases endocannabinoid levels in brain. Increasing LA from 1 en% to
8 en% elevated (a) 2-AG and (b) AEA in hypothalamus/hippocampus region (Paper I) and cerebral
cortex (Paper II and III). (c) The increase (%) in brain endocannabinoid levels was independent of
brain structure and time-point of exposure. Open bars represent low fat diets (12.5 en%), coarse
bars medium fat diets (35 en%), vertical lines high fat diets (60 en%) and dotted bars represent
Atlantic salmon (35 en% fat). Bar colors indicate light gray 1 en% diets, gray 8 en% LA and
dark gray 8 en% LA + 1 en% EPA/DHA. Statistical differences are presented in individual papers.
Abbreviations: AEA anandamide, FO mice fed ﬁsh oil (FO) salmon, LF low fat diet, HF high fat,
MF medium fat, SO mice fed soybean oil (SO) salmon.
fatty acid composition as long as minimum requirements are met (Lauritzen et al.,
2001). Although the increase in brain 2-AG and anandamide caused by the 8 en%
LA diets were not statistically signiﬁcantly from diets of 1 en% LA, the biological
signiﬁcance remains to be elucidated.
Brain levels of 2-AG and anandamide were less affected by dietary LA than
the liver. The increase in brain n-6 HUFA (9 %) was considerably lower than in
peripheral tissue such as liver (42 %) and RBC (37 %, Paper I), and eWAT (29%
Paper II and 72% Paper III). The lower sensitivity of dietary LA on endocannabi-
noid levels in brain compared to peripheral tissues suggests that brain lipids and
endocannabinoid levels are physiologically more stable and less inﬂuenced by
changes in dietary fatty acids (Wood et al., 2010; Di Marzo et al., 2010).
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Endocannabinoids and appetite
The higher food intake in mice fed 8 en% LA compared to 1 en% LA in the
high fat diets (Paper I) is likely to be induced by a sustained hyperactivity of
the endocannabinoid system both peripherally and centrally to increase appetite
and reduced satiety (Williams and Kirkham, 1999; Kirkham et al., 2002). The
elevation of brain 2-AG and anandamide levels in mice fed 8 en% in medium fat
diets (Paper I, II and III) may not have been sufﬁcient to stimulate the hyperphagic
behavior seen in mice fed 8 en% LA in a high fat diet (Paper I). Endogenous
endocannabinoid stimulation cause a modest overeating compared to exogenous
cannabinoid stimulation (Williams et al., 1998; Williams and Kirkham, 1999).
The food intake ﬂuctuated during the 14-16 weeks of feeding, peaking every 2
(Paper II and III, Figure 4.3 (a)) and 3 weeks (Paper I, Figure 4.3 (b)). The high fat
diets of 8 en% LA followed the ﬂuctuations but at a higher intake than the other
diets (Paper I, Figure 4.3(b))indicating that the overeating is an ampliﬁcation of
endocannabinoid activity associated with the normal, episodic pattern of meal-
taking (Kirkham and Williams, 2001).
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Figure 4.3: Weekly food intake. (a) Increasing dietary LA from 1 en% to 8 en% increased food
intake in high fat diets (60 en%). (b) Food intake and eating pattern were similar in mice fed low
fat (12.5 en%) and medium fat diets (35 en%, Paper II and III). Mice in Paper I were housed 2
per cage whereas mice in Paper II and III were housed individually. Statistical differences are
presented in individual papers. Abbreviations: FO diet of salmon fed ﬁsh oil, HF high fat diet, LF
low fat diet, MF medium fat diet, SO diet of salmon fed soybean oil.
4.2.4 Peripheral effect of endocannabinoid activation
Increasing dietary LA from 1 en% to 8 en% signiﬁcantly increased liver AA -PL
with a subsequent elevation in liver 2-AG and anandamide (Paper I, II and III, Fig-
ure 3.2). The elevated endocannabinoid activity in mice fed 8 en% LA compared
to 1 en% LA was associated with higher feed efﬁciency; resulting in higher weight
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gain per calorie consumed, which caused adipose tissue accumulation regardless
of amount of dietary fat (Paper I, II and III) and increased adiposity (Paper I, Ta-
ble 3.2). Dietary LA of 8 en% resulted in adipocyte hypertrophy, adipose tissue
inﬂammation and elevated circulating leptin, factors that may increase the risk of
metabolic disorders associated with obesity (Paper II, III).
Energy balance
The most striking ﬁndings in the present work are 1) that a low fat diet can be
made obesogenic by selective inclusion of 8 en% LA (Paper II) and 2) the obe-
sogenic properties of a high fat diet, commonly used to induce obesity in animal
models, can be reversed by selectively reducing dietary LA to 1 en% (Paper I).
Our ﬁndings imply that low fat human diets could be made more effective in re-
ducing obesity if LA is lowered to near 1 en%. Indeed, total dietary fat intake may
not need to be lowered if LA is selectively lowered.
Diets of 1 en% containing higher level of monounsaturated and saturated fat
(Table 3.1) did not increase weight gain or adiposity compared to 8 en% LA diets
demonstrating that dietary LA is more obesogenic than saturated and monounsat-
urated fat. Our data support the notion that weight gain and adipose tissue accu-
mulation depends on the quality of the fat rather than quantity (Massiera et al.,
2003; Ailhaud et al., 2008; Madsen et al., 2008; Matias et al., 2008a,b).
Several studies report higher feed intake, weight gain and greater adiposity
from oils rich in LA such as soybean and safﬂower oil (Dayton et al., 1966; Cun-
nane et al., 1985; Ikemoto et al., 1996; Okuno et al., 1997; Takahashi and Ide,
2000; Massiera et al., 2003; Pellizzon et al., 2002; Javadi et al., 2004; Madsen
et al., 2008). But the adipogenic effect of n-6 PUFA is controversial. Lower adi-
pose tissue accumulation has been reported in mice fed soybean and safﬂower oil
compared to saturated fat (Shimomura et al., 1990; Takeuchi et al., 1995; Matsuo
et al., 2002). Differences in experimental setup, type and amount of carbohy-
drates, length of feeding and the use of different rodent strains may inﬂuence
the result leading to different effects of dietary LA (Madsen et al., 2010). The
opposing effect of LA on adipose tissue development was found to involve diet-
induced differences in cAMP levels which can affect adipose tissue differentiation
and the expression of UCP1 in adipose tissue (Madsen et al., 2008). Higher pro-
tein/carbohydrate ratio (Madsen et al., 2008) and pharmacological blockade of
CB1 (Esposito et al., 2008; Sugamura et al., 2009) increase cAMP levels. El-
evated cAMP levels induce thermogenesis by increasing expression of PGC-1α
and UCP1 in brown adipose tissue (Cannon and Nedergaard, 2004). Pharmaco-
logically blocking the CB1 receptor induced UCP1 expression in white adipocytes,
accompanied by an increased mitochondrial biogenesis and insulin sensitivity
(Perwitz et al., 2010). We aimed at measuring UCP1 in white adipose tissue
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to investigate if the leaner phenotype in mice fed 1 en% LA and 8 en% LA +
1 en% EPA/DHA was a result of higher energy expenditure. Lower CB1 activa-
tion in mice fed 1 en% LA and supplemented with EPA/DHA may have induced
UCP1 expression and trandifferentiation of white adipocytes to a brown pheno-
type as observed in cell culture (Perwitz et al., 2010). However, long-term storage
(18 months in -80◦) and eWAT thawing in transit during shipment degenerated
mRNA quality, making it unsuitable for real time-qPCR.3
Lipid metabolism
The higher adiposity in mice fed 8 en% LA could not be explained by differences
in liver mRNA expression of the lipogenic transcription factor SREBP-1c and its
target genes ACC1 and FAS. An increased basal rate of fatty acid synthesis in
liver by pharmacological and dietary activation of the CB1 receptor suggest that
an early endocannabinoid-mediated increase in de novo lipogenesis is a critical
component of diet-induced obesity in mice (Osei-Hyiaman et al., 2005). As pre-
viously reported (Kim et al., 1999, 2002; Tandy et al., 2009; Piscitelli et al., 2011)
we found that the expression of SREBP-1c, ACC1 and FAS were more closely
related to the total PUFA content in the high fat diets than dietary LA (Paper I,
Supplementary). Sugar is a strong inducer of SREBP-1c (Madsen et al., 2010)
and may explain why mRNA levels of SREBP-1c, FAS and ACC1 did not differ
in mice fed medium fat diets (Paper I).
Supplementing the 8 en% LA diets with 1 en% EPA/DHA reduced AA -PL
and 2-AG in liver (Figure 3.2) and reversed the adipogenic effect of the 8 en%
LA diets (Paper I, Table 3.2). We only observed lower liver mRNA expression
of SREBP-1c, ACC1 and FAS in mice supplemented with EPA and DHA in the
high fat diet, but not statistically different from mice fed 8 en% LA (Paper I). Our
results suggest that altered expression of SREBP-1c and its target enzymes is not
the main pathway involved in preventing weight gain in diets of 1 en% LA after
long-term feeding (Paper I).
The leaner phenotype of mice fed 1 en% LA and 8 en% LA + EPA/DHA
may be due to higher adiponectin levels caused by lower CB1 activation in pe-
ripheral tissue (Bensaid et al., 2003; Gary-Bobo et al., 2006; Matias et al., 2006b).
Adiponectin can increase fatty acid oxidation and energy consumption (Yamauchi
et al., 2001a). Mice fed 8 en% LA had lower adiponectin and higher adiposity than
mice fed 1 en% LA (Paper I) which pose a greater risk for developing insulin re-
sistance (Yamauchi et al., 2001b). Insulin levels did not differ between the dietary
treatments (Paper I and II) suggesting that the mice were still insulin sensitive.
3Most tissue samples had RNA Integrity Number (RIN, analyzed by Bioanalyser) of less than
6 which we considered to low for RT-qPCR.
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Insulin resistant adipocytes loose their ability to regulate endocannabinoid action
(D’Eon et al., 2008; Di Marzo et al., 2009b) which may further aggravate the
metabolic state of mice ingesting 8 en% LA.
Adipose tissue
Mice fed 8 en% LA had higher concentration of AA in eWAT than mice fed 1
en% LA (Paper II). Higher substrate availability for endocannabinoid synthesis
may have inﬂuenced CB1 activity in adipose tissue. An overactivity of CB1 acti-
vation in mice fed 8 en% LA can have contributed to the higher adiposity (Paper
I) and adipose tissue hypertrophy (Paper II and III) by a more rapid differentiation
of pre-adipocytes to mature adipocytes (Matias et al., 2006b), increased adipocyte
proliferation (Gary-Bobo et al., 2006), induction of accumulation of lipid droplets
(Matias et al., 2008b) and facilitated fatty acid uptake by the adipocytes (Cota
et al., 2003). Histology was only intended to visualize differences between the
dietary treatments, therefore adipose tissue was only collected from only two ani-
mals per diet, representing the average body weight of their respective treatments.
When histology was performed (18 months years after sacriﬁce) the techniques,
equipment and software available were improved, but we did not have sufﬁcient
power (n = 2) to perform statistics (Paper II and III). However, our ﬁnding that
dietary LA affect adipose tissue morphology is consistent with previous reports
(Ezaki et al., 1992; Cleary et al., 1999).
Immunohistochemical analysis of adipose tissue by staining for the macrophage
marker F4/804 demonstrated more macrophage inﬁltration in eWAT of mice fed
8 en% LA than in mice fed 1 en% LA in both low fat and medium fat diets (Pa-
per II and III). The higher inﬂammation in adipose tissue of mice fed 8 en% LA
compared to 1 en% LA further supports the hypothesis of a more obesity-prone
phenotype from high dietary levels of LA. It was recently shown that the expres-
sion of inﬂammatory markers and macrophage marker genes were higher in iWAT
than eWAT (Du et al., 2011). We were not able to measure the expression of in-
ﬂammatory markers in adipose tissue due low quality of mRNA and loss of tissue
during shipment as previously mentioned.
The lower macrophage inﬁltration in adipose tissue of mice fed 1 en% LA
(Paper II) and FO salmon (Paper III) may be due to higher tissue levels of EPA
and DHA (Figure 3.2). Diets enriched with n-3 PUFA reduce adipose tissue
inﬂammation in diet-induced obesity (Todoric et al., 2006; Huber et al., 2007;
Perez-Echarri et al., 2008). The mechanism by which EPA and DHA reduce
macrophage-induced adipose tissue inﬂammation is mediated by stimulation of
the fatty acid receptor GPR120 (Oh et al., 2010). EPA and DHA can be converted
4F4/80 is a glycoprotein that increases as macrophages mature (Lin et al., 2005)
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to metabolic products such as resolvins and protectins with anti-inﬂammatory ac-
tions independent of the state of obesity (Bannenberg et al., 2005). In our work
dietary LA of 8 en% appears to decrease the anti-inﬂammatory properties of EPA
and DHA (Paper III). Sucrose counteracts the anti-inﬂammatory effect of ﬁsh oil
in adipose tissue (Ma et al., 2011) and together these data demonstrate that the
background diet inﬂuence the anti-adipogenic and anti-inﬂammatory properties
of EPA and DHA. The type of dietary fat seems to be an important determinant in
adipose tissue inﬂammation (Paper II and III).
In contrast to mice prenatally exposed to 1 en% (Paper I), long-term feeding
of 1 en% LA from adulthood did not prevent weight gain and adiposity com-
pared to 8 en% LA (Paper II). Prior to arriving at our facility the mice were fed
a diet based on soybean oil (NIH #31M, Paper II and III). We estimate, using the
Lands equation (Lands et al., 1992) that the NIH #31M diet yields 72% n-6 HUFA
in tissue phospholipids, identical to our 8 en% LA diets (Table 3.1). Metabolic
changes such as induced lipogenesis and deposition of lipid droplets in response to
increased endocannabinoid activity have been shown to occur before onset of obe-
sity (Xu et al., 2003; Osei-Hyiaman et al., 2005; Matias et al., 2008b). Therefore,
an already elevated endocannabinoid tone combined with abundant carbohydrates
and fat may have promoted adipose tissue expansion possibly overriding the anti-
adipogenic effect of 1 en% LA (Paper II). Mice fed 8 en% in the low fat diet
gained considerably more weight than mice fed a low fat diet of 1 en% LA after
8 weeks of feeding (Figure 3.3). We cannot exclude that the same is the case for
medium fat diets after 16 weeks of feeding. Thus when reducing dietary LA in
adults, especially in diets with high fat content, longer feeding periods appear to
be necessary to affect body weight and weight gain (Paper II).
4.2.5 Endocannabinoid levels in Atlantic salmon
In this work we demonstrate the presence of endogenous 2-AG and anandamide
in liver of Atlantic salmon (Paper III). Endogenous cannabinoids has previously
been reported in ﬁsh brains (Cottone et al., 2005; Valenti et al., 2005). Replacing
ﬁsh oil with soybean oil in feed for Atlantic salmon introduce high dietary levels
of LA (Table 3.1) altering the fatty acid proﬁle of salmon ﬁllet and liver. Salmon
fed soybean oil have higher levels of LA and lower levels of EPA and DHA in liver
and ﬁllet compared to salmon fed ﬁsh oil 6 months feeding (Paper III). Similar to
what we observed in mice (Paper I and II), increasing dietary LA elevated liver
AA (89%), subsequently elevating 2-AG (42%) and anandamide (36%) in salmon
liver with considerably higher levels 2-AG than anandamide (Paper III, Figure
3.2).
We observed higher liver lipid accumulation in Atlantic salmon when ﬁsh oil
was replaced by soybean oil, consistent with previous studies replacing vegetable
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oil with ﬁsh oil in feed for Atlantic salmon (Jordal et al., 2007; Torstensen et al.,
2011). Osei-Hyiaman et al. (2005) found that stimulation of the CB1 receptor in
mice liver induce the expression of SREBP-1c, FAS and ACC1 activity and stim-
ulate de novo fatty acid synthesis . In Atlantic salmon, replacing ﬁsh oil with a
blend of vegetable oils (rapeseed, palm and Camelina oils) up-regulated the ex-
pression of SREBP-1c and FAS (Morais et al., 2011a), and affected cholesterol
and lipoprotein metabolism (Morais et al., 2011b). It is therefore likely that an
elevated endocannabinoid tone in Atlantic salmon fed soybean oil stimulated hep-
atic de novo fatty acid synthesis (Paper III).
We did not ﬁnd any effect on body weight or visceral somatic index (VSI)
in salmon when soybean oil replaced ﬁsh oil for 6 months. Higher body weight
has previously been reported in Atlantic salmon fed vegetable oils for 12 months
(Torstensen et al., 2005, 2011), suggesting that longer feeding period (> 6 months)
may be required in to detect differences in body weight and visceral fat stores in
Atlantic salmon.
In the present study Atlantic salmon was fed soybean oil, one of the major di-
etary source of LA, resulting in 2.5 g LA / 100 g ﬁllet and 0.7 g EPA + DHA / 100
g ﬁllet. Thus replacing ﬁsh oil with soybean oil represents an extreme model in
which vegetable oils are used as alternative lipid source in feed for Atlantic salmon
(Table 4.1). Our ﬁndings of elevated liver endocannabinoid and lipid accumula-
tion in Atlantic salmon fed soybean oil suggest that future ﬁsh oil replacement in
farmed Atlantic salmon should pay attention to the choice of vegetable oils with
regards to LA content.
Table 4.1: LA and EPA/DHA in a 200 g serving of farmed Atlantic salmon
Source of salmon LA (en%)1 EPA/DHA (en%)
Norwegian farmed2 1.4 1.9
Paper III (FO) 0.4 1.6
Paper III (SO) 2.3 0.6
1 Based on a 2000 kcal diet, 2 (NIFES, 2011b). No data
available for wild salmon (NIFES, 2011b). Abbreviations:
FO salmon fed ﬁsh oil, SO salmon fed soybean oil.
4.3 Fish versus supplements - source of EPA and
DHA
Supplementing the 8 en% LA diets with 1 en% EPA/DHA from ﬁsh oil prevented
the increase in tissue AA -PL, liver anandamide and brain 2-AG levels, and re-
duced the adipogenic effect of the 8 en% LA diets (Paper I). Consistent with a
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recent report (Ibrahim et al., 2011), we found that mice fed Atlantic salmon ac-
cumulated more adipose tissue and had higher leptin and insulin levels (Paper III)
than mice fed a casein diet (Paper II), despite the lowest endocannabinoid lev-
els in liver. Higher levels of EPA and DHA in salmon diets (2-3 en%) did not
prevent the development of obesity as we observed by supplementation of 1 en%
EPA/DHA from ﬁsh oil (Paper I). The salmon based diets promoted obesity (Pa-
per III). The ﬁnding of higher adiposity in mice fed salmon compared to casein
suggests an interacting effect between dietary fat and salmon protein in terms of
weight gain, which is supported by the ﬁnding of higher body weight in mice
fed salmon protein (defatted, no EPA and DHA) compared to whey -and casein
protein (Haldis H. Lillefosse personal communication). Chronic long-term con-
sumption of Atlantic salmon, soybean oil fed in particular (Paper III), resulted in
higher liver (20-40% higher than Paper I and II) and muscle weights (Table 3.2).
Higher organ weights of mice fed Atlantic salmon may result from higher ectopic
fat deposition. Mice fed Atlantic salmon also had higher plasma levels of insulin
(Paper III) compared to mice fed casein diets (Paper II) which may indicate in-
sulin resistance and a diabetic phenotype (Ibrahim et al., 2011). Insulin resistance
is associated with ectopic fat accumulation and increase the risk of developing
type 2 diabetes (Gastaldelli, 2011). Insulin resistant adipocytes loose their ability
to regulate endocannabinoid action (D’Eon et al., 2008; Di Marzo et al., 2009b),
which may explain the exacerbated effects of the SO salmon diet compared to the
FO salmon diet in terms of adipose tissue hypertrohphy and inﬂammation (Paper
III).
Enhanced fat absorption in mice fed Atlantic salmon (Ibrahim et al., 2011)
may have lead to higher weight gain in mice fed Atlantic salmon (Paper III)
compared to casein (Paper II). The macronutrient digestibility and bioavailability
may be differentially affected by salmon and milk protein (Gilbert et al., 2011).
Atlantic salmon provide a better amino acid balance than milk protein (casein),
which is low in amino acids such as glycine and lysine and depleted of cystein5.
A different amino acid composition may inﬂuence the availability of macronutri-
ents. In a diet with excess calories (Paper III) and limited physical activity higher
bioavailability and macronutrient utilization from salmon protein may not be ben-
eﬁcial in terms of body weight. In humans, inclusion of ﬁsh (cod or salmon 3 x
150 g/week) contributed to additional weight loss compared to an isocaloric con-
trol diet in an energy restricted regime (Thorsdottir et al., 2007), and decreased
inﬂammatory markers (Ramel et al., 2010). Daily ﬁsh intake in an energy re-
stricted diet had beneﬁcial effects on glucose, insulin and lipid metabolism (Mori
et al., 1999). Cod protein protected against obesity-linked insulin resistance and
glucose intolerance in rats fed a high fat/high sucrose diet (Lavigne et al., 2001),
5cystein was added to casein diets
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and improved insulin sensitivity in insulin-resistant subjects (Ouellet et al., 2007,
2008) suggesting differential effect of different ﬁsh proteins. Epidemiological
studies have shown that a Mediterranean type diet rich in fruits, vegetables and
ﬁsh is health promoting and may facilitate weight maintenance (Shubair et al.,
2005; Schulze et al., 2006) emphasizing the importance of a balanced diet. A
long-term intake of a diet based solely on proteins from Atlantic salmon does not
appear to be beneﬁcial, at least in terms of weight management and hormonal
levels.
4.4 Linoleic acid lowering to increase tissue EPA and
DHA
We used the Lands equation (Lands et al., 1992) to predict AA -PL composition as
the percent n-6 HUFA from dietary intakes of LA, ALA, AA and EPA/DHA, with
good concurrence between calculated and experimental values in all papers (Table
3.1). As predicted, increasing dietary LA from 1 to 8 en% increased the percent
of n-6 HUFA in RBC from 47% to 74% (Paper I) and 62% to 73% (Paper II),
simultaneously decreasing the n-3 index from 12 to 4.5 (Paper I) and 9 to 5 (Paper
II). The n-6 HUFA can be used as an indicator of disease risk as it models the
relative amount of AA -PL available as precursors for eicosanoid derivates of AA,
and the proportion of n-6 in tissue HUFA is associated with CVD rates (Lands,
2003). An n-3 index of 8 or higher is associated with low risk of cardiovascular
disease whereas 4 or lower increase CVD risk (Harris and von Schacky, 2004).
It was recently stated that an n-3 index of 8-11, and/or tissue n-3 HUFA of more
than 50% would protect 98% of the population from mental illness (Hibbeln et al.,
2006; Global Omega-3 Summit, 2011).
Consistent with prior studies (Bourre et al., 1990a; Liou et al., 2007; Novak
et al., 2008; Igarashi et al., 2009; Munakata et al., 2009; Guesnet et al., 2011)
our results demonstrate that the elongation and desaturation of ALA to EPA and
DHA, and/or the acylation of EPA and DHA into the sn-2 position of tissue phos-
pholipids are considerably more effective when dietary LA is 1en%. Increasing
dietary LA from 1 en% to 8 en% signiﬁcantly reduced EPA in RBC, liver (Paper I,
II and III) and eWAT (Paper II and III). A high dietary exposure of 8 en% LA from
gestation caused a more pronounced reduction in DHA (liver; MF 32% and HF
18%, RBC; MF 30% and HF 27%, Paper I) compared to adulthood (liver; LF 18%
and MF 5%, RBC; LF 8% and MF 12%, Paper II). Our results demonstrate that
dietary fat cause more persistent changes when given in high doses early in life. In
humans, the conversion of ALA to EPA and DHA is believed to be low, and ALA
is not considered to be a signiﬁcant source of EPA and DHA in the human diet
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(Brenna et al., 2009). High dietary intake of LA is preventing the conversion of
ALA to EPA and DHA as several human trials have demonstrated that sufﬁcient
lowering of dietary LA increase tissue levels of EPA and DHA (Clark et al., 1992;
Liou et al., 2007; Munakata et al., 2009).
The aquaculture industry currently requires more than 1 kg wild ﬁsh raw mate-
rial to produce 1 kg farmed salmon (FKD, 2009). Dietary guidelines recommend
intakes of 4-10 en% n-6 PUFA (Table 2.1) which will require 1 - 2 g EPA/DHA
per day to achieve 50% n-3 in tissue HUFA (Table 2.2), estimated to reduce the
burden of diseases such as cardiovascular and mental illnesses (Hibbeln et al.,
2006). Our data show that a dietary intake of 1 en% LA and 1 en% ALA (Paper I)
results in 50% n-3 HUFA in tissue of mice without EPA and DHA supplementa-
tion. When dietary ALA was reduced from 1 en% (Paper I) to 0.5 en% (Paper II),
the amount of n-3 HUFA in RBC decreased by 40%. However, the n-3 index was
still ≥ 8 (Table 3.1, sufﬁcient to give good cardiovascular protection (Harris and
von Schacky, 2004). At least in rodents, reducing LA to increase EPA and DHA
appears to be more efﬁcient than supplementing DHA to high LA diet (Novak
et al., 2008). Therefore, in order to elevate tissue EPA and DHA, emphasis should
be on reducing dietary LA in addition to EPA/DHA supplementation.
4.5 Human relevance
There is dramatic progress in obesity research, but no safe and potent weight-
reducing drugs are currently available. The discovery of leptin in 1994 was over-
shadowed by clinical studies ﬁnding that the fat-reducing effects of leptin were
limited to a few patients with congenital leptin deﬁciency (Farooqi et al., 1999).
The endocannabinoid system represents a new and promising target to reduce obe-
sity. Pharmacological blockade of the CB1 receptor is effective in treating obe-
sity and related metabolic derangements (Bensaid et al., 2003; Jbilo et al., 2005;
Van Gaal et al., 2005; Després et al., 2005; Matias et al., 2006b; Christopoulou
and Kiortsis, 2011). However serious psychiatric side effects, including suicidal
risk (Christensen et al., 2007), caused marketplace withdrawal of rimonabant, a
selective CB1 antagonist, and have impaired further pharmaceutical development.
In lieu of a better anti-obesity drug, we here present a dietary approach to resolve
an underlying cause of endocannabinoid hyperactivity. LA lowering may prove to
be a safe and viable way to reduce obesity and associated metabolic disorders by
reducing substrate availability for endocannabinoid synthesis.
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4.5.1 Doses of dietary fatty acids
Dietary LA of 8 en% is based on current US intakes (Blasbalg et al., 2011), con-
sidered adequate by the Institute of Medicine of the US National Academy of
Sciences (IOM, 2005) and within most dietary recommendations of 5-10 en% n-6
PUFA (see Table 2.1). The increasing use of soybean oil in the US has also in-
creased the availability of ALA to 1 en% (Blasbalg et al., 2011). The doses of LA,
ALA and EPA/DHA used in the individual papers underlying the present thesis
are listed in Table 4.2 with the rational for the dose used.
Table 4.2: Doses of fatty acids in Paper I, II and III
Paper Fatty acid Dose (en%) Rationale
I, II
LA
1 evolutionary levels
8 current US intake
III 1 present in FO salmon8 present in SO salmon
I
ALA
1 evolutionary levels
II 0.4 to match ALA in FO salmon0.9 to match ALA in SO salmon
I
EPA/DHA
1 to reduce tissue n-6 HUFA to levels from 1en% LA diet
III 2.7 level in FO salmon1.8 level in SO salmon
Abbreviations: en% percent energy, FO ﬁsh oil, HUFA highly unsaturated fatty acid (> 20
carbons), SO soybean oil.
In Paper I we calculated the amount of EPA and DHA needed in a 8 en% LA
diet to obtain the same amount of n-6 HUFA (AA -PL) in RBC as a diet of 1
en% LA by using the Lands equation (Lands et al., 1992). The different levels of
fatty acids were added to diets of 35 en% fat, the upper limit of recommended fat
intake (Nasjonalt Råd for Ernæring, 2011; USDA, 2010). Dietary fat of 60 en%
fat corresponds to a very high fat diet commonly used to induce obesity animal
models.
In Paper II, the dietary fatty acid proﬁle of LA and ALA was set up to match
the fatty acid proﬁle of Atlantic salmon raised on ﬁsh oil or soybean oil (Paper
III) in a low fat (12.5 en%) and a medium fat (35 en%) diet.
In Paper III, replacing ﬁsh oil with soybean oil in feed for Atlantic salmon
increased dietary LA from 1 en% to 10 en%, and dietary ALA from 0.4 to 1 en%,
if salmon ﬁllet was the sole source of dietary fat. A blend of oils were added to
the salmon diets to increase dietary fat content to 35 en% and preserve the fatty
acid proﬁle of LA and ALA in ﬁsh ﬁllets (Table 3.1).
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4.5.2 Time-point of exposure to linoleic acid
Dietary LA appears to be more adipogenic, resulting in higher adiposity, when
high amounts (8 en%) are introduced prenatally (Paper I), compared to adulthood.
Early exposure to high dietary levels of fat (35 and 60 en% fat) lead to persis-
tent elevated endocannabinoid levels in peripheral tissue (Figure 3.2). Increased
endocannabinoid levels were associated with higher adipose tissue accumulation
and adiposity, conditions that were further aggravated when the diet contained 8
en% LA (Table 3.2). Our results support a recent study where exposure to a high
fat diet in the developmental period exacerbated the effect of a high fat diet later
in life (Bruce et al., 2009; Massiera et al., 2010). Changes occurring during de-
velopment appears to be persistent and affect disease outcome later in life (Bruce
et al., 2009). A defective leptin signaling caused by a diet of 8 en% LA may lead
to a chronic state of perceived starvation (Friedman and Halaas, 1998). In addi-
tion an altered nutrient preference and increased motivation to eat arising from a
chronically elevated endocannabinoid system following a high fat/high LA ma-
ternal diet may predispose children to obesity and associated metabolic disorders
and/or accelerate the development of obesity and increase vulnerability to develop
metabolic complications as adults.
Presently in the United Stated nearly 2/3 of the adult population is at least
overweight (Flegal et al., 2002), many of which are diet-induced. This results in
a situation where the majority of pregnancies are under conditions of less than
optimal health (i.e. overweight and eating a high fat/high LA diet). There is a
risk that these conditions imprint a metabolic condition onto the offspring thereby
pushing the set point for body weight and adiposity higher. This could cause the
next generation to be more metabolically efﬁcient, making it harder to maintain a
healthy phenotype (Grove et al., 2005). Overall, the results presented here point
out the importance of a balanced diet, especially in maternal and childhood diets,
with emphasis on n-3 and n-6 intakes.
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Conclusions
He who knows best knows how little he knows. - Thomas Jefferson
The work presented in this PhD shows that:
• Compared to 1 en% LA, dietary LA of 8 en% increased tissue levels of
AA in phospholipids and elevated 2-AG and anandamide in liver associ-
ated with higher feed efﬁciency, increased weight gain and adipose tissue
accumulation and inﬂammation independent of amount of dietary fat.
• Mice prenatally exposed to 8 en% LA accumulated more adipose tissue re-
sulting in higher adiposity index and higher leptin levels than mice exposed
to 8 en% LA from young adulthood.
• High dietary levels of LA increased endocannabinoid levels in liver of At-
lantic salmon. Mice fed Atlantic salmon raised on soybean oil had higher
2-AG and lower EPA and DHA concentrations in liver, gained more weight
and had more adipose tissue inﬂammation than mice fed Atlantic salmon
raised on ﬁsh oil.
We believe that elevating dietary LA from 1 en% to 8 en%, and current dietary
advices regarding n-6 PUFA, contributes to the obesity epidemic by:
• Increasing AA and lowering EPA and DHA in the phospholipid pool.
• Elevating endocannabinoid activity.
• Higher caloric intake and feed efﬁciency.
• Inducing weight gain and adiposity.
• Adipose tissue hypertrophy.
• Increasing adipose tissue inﬂammation.
• Of note, a 60 en% fat diet did not induce obesity when dietary LA was 1
en%.
Future directions
The more that you read the more you will know. The more that
you learn the more places you’ll go! - Dr. Seuss
Human intervention trial
Dietary guidelines recommend replacing saturated fat with vegetable oils and hav-
ing an n-6 PUFA/LA intake of 5-10 en% (Table 2.1). A diet of 12.5 and 35 en%
fat (within the general dietary guidelines of total dietary fat (20-35 en% fat) with
9 en% PUFA (LA:ALA ratio of 8:1, Paper I, and 8:0.5, Paper II and III) elevated
endocannabinoid activity, increased weight gain and adiposity, and caused adi-
pose tissue hypertrophy and inﬂammation. Based on our results from modeling
the ecological changes in dietary LA in mice, we hypothesize that 8 en% LA,
with a low intake of n-3 PUFA, will induce endocannabinoid hyperactivity and
may substantially increase the risk of metabolic disorders and obesity in humans.
We acknowledge that a positive correlation between increasing intake of soybean
oil, the major dietary source of LA, and the rise in the prevalence of obesity in
the US during the 20th century and our animal data are not sufﬁcient to explain
causality. It is therefore of great importance to conduct a long-term human dietary
intervention trial with intakes of 1 en% LA and 8 en% LA to translate the animal
data and conﬁrm the causal role of high dietary LA intakes to endocannabinoid
hyperactivity and obesity in humans. Reducing dietary LA from 8 en% to 1 en%
in overweight subject may prove the safe and favorable effect of lowering dietary
LA to diminish endocannabinoid hyperactivity to reduce obesity and associated
metabolic disorders. Such a dietary approach will have widespread beneﬁcial
health implications related to obesity and metabolic syndrome. In addition reduc-
ing dietary LA to less than 2 en% is likely to increase the conversion of ALA to
EPA and DHA in human tissue to reduce the global burden of chronic diseases
(Hibbeln et al., 2006).
Dietary fat, carbohydrates and endocannabinoid hyperactivity
Dietary recommendations emphasizing the replacement of saturated fat with PUFA
and increase the intake of complex carbohydrate turn many people to fat-free prod-
ucts which often replace fats with sugar and reﬁned carbohydrates.
The background diet affects the adipogenic effect of both n-3 and n-6 fatty
acids (Madsen et al., 2008; Ma et al., 2011). A high carbohydrate diet elevate
insulin levels which can induce de novo fatty acid synthesis and expression of
SREBP-1c (Madsen and Kristiansen, 2010). The type of carbohydrates has dif-
ferent effect on insulin secretion. Carbohydrates with a high glycemic index, such
as sucrose, increase the adipogenic effect of fat more than carbohydrates with low
glycemic index, such as starch (personal communication master thesis Ragnhild
Jarlsby). Hence dietary changes in insulin and cAMP signaling might translate
into different effects on adipose tissue growth (Madsen and Kristiansen, 2010).
Cyclic AMP is an important second messenger in regulation of adipose tissue
metabolism where it can increase lipolysis and induce the expression of UPC1
(Madsen and Kristiansen, 2010). UCP1 is exclusively expressed by brown adipoc-
ytes (Nicholls and Rial, 1999) where it regulates energy expenditure by increasing
thermogenesis (Cannon and Nedergaard, 2004). Pharmacological blockage of the
CB1 receptor by rimonabant increase cAMP, induce the transdifferation of white
adipocytes to a brown phenotype and increase the expression of UCP1 which
may increase and/or prevent weight loss. The work from this thesis has gener-
ated a platform from which we can study the molecular and mechanistic effects
of dietary LA and endocannabinoid hyperactivity and energy expenditure. We
hypothesize that a low LA diet of 1 en% will lower CB1 activity and induce the
transdifferation of white adipocytes to a brown phenotype thus increasing energy
expenditure by elevating UCP1 levels. Lower CB1 activity is likely to improve
metabolic functions associated with obesity, but it remains to be elucidated if the
effect of LA on CB1 activity is dependent on source and amount of dietary carbo-
hydrates (Figure 4.4).
Figure 4.4: Pharmacological stimulation of the cannabinoid receptor CB1 inﬂuence cAMP and
UCP1. Stimulation of CB1 inhibits adenylate cyclase and decrease cAMP levels. Antagoniz-
ing CB1 by rimonabant increases the expression of UCP1 thereby increasing energy expenditure.
cAMP levels are inﬂuenced by the dietary protein/carbohydrate ratio. High dietary protein increase
cAMP levels and induce the expression of UCP1 in a COX and PGE2 dependent fashion.
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